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CHAPTER I 
 
INTRODUCTION 
 
The Skeleton 
The functions of bones range from providing mechanical support to soft tissues 
to maintaining mineral homeostasis. These functions are accomplished by continuous 
tissue renewal, or bone remodeling, which involves the removal of old or damaged bone 
by osteoclasts (bone resorption ) and the subsequent replacement of new bone formed 
by osteoblasts (bone formation). In normal bone remodeling, a balance between bone 
resorption and formation is tightly regulated to ensure a relatively constant bone mass 
and mechanical strength in mature healthy bone. Nonetheless, under certain 
pathological conditions an imbalance between bone resorption and formation may occur, 
leading to the development of bone disorders. One common disorder of bone 
remodeling, osteoporosis, is characterized by low bone mass; it causes bone fragility 
and an increased fracture risk (2001). At present, most treatments for osteoporosis are 
symptomatic in the form of inhibiting bone resorption, rather than stimulating bone 
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formation, due to the limited availability of anabolic approaches (Karsenty 2003). Further 
understanding of osteoblast differentiation may shed light on new and more potent 
treatments of osteoporosis. 
 
Osteoblast Differentiation 
Osteoblasts are the bone forming cells that originate from mesenchymal stem 
cells, the pluripotent cells residing in the bone marrow, muscles, and fat (Caplan and 
Bruder 2001; Jiang, Jahagirdar et al. 2002). The differentiation of osteoblasts is an 
adaptive process, modulated by mechanical loads, circulating calcium level, sex steroids, 
Bone Morphogenetic Proteins (BMPs), Parathyroid hormone (PTH), Transforming 
Growth Factor beta (TGFβ) and other factors (Harada and Rodan 2003). These 
extracellular signals are integrated by intracellular signaling molecules and transcription 
factors, which are subsequently turned on or off in a tissue-specific manner. They 
selectively transactivate osteoblast related and/or specifc genes, triggering and 
maintaining the osteoblast differentiation process. The differentiation program can be 
divided into several stages, including proliferation, extracellular matrix deposition, and 
mineralization. 
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Figure 1. Osteoblast differentiation. Osteoblasts arise from pluripotent mesenchymal 
stem cells under the control of transcription factors including Runx2, Osterix (OSX), and 
activating transcription factor 4 (ATF4). Along differentiation, markers genes such as 
Collagen type I (Col-I) and alkaline phosphatase (ALP) in early osteoblasts and bone 
sialoprotein (BSP) and osteocalcin (Ocn) in mature osteoblasts will be gradually turned 
on. Osteoblastogensis is regulated by several extracellular signals including bone 
morphogenic protein 2 (BMP2) and transforming growth factor β (TGFβ).  
 
 
 
 4 
 
During the early stages, alkaline phosphatase (ALP) and type I collagen (Col1α1) 
are first expressed, followed by the expression of late, and more specific, osteoblast 
genes such as bone sialoprotein (BSP), osteopontin (OPN) and osteocalcin (OCN).  The 
expression levels of these genes are frequently used as indicators for the level of 
differentiation and activity of osteoblasts. After maturation, some osteoblasts become 
osteocytes (Dallas and Bonewald 2010), whereas some become lining cells and some 
undergo apoptosis (Manolagas 2000). In order to maintain the bone homeostasis, this 
differentiation program is intimately coupled to local areas of bone resorption and 
therefore replenishes osteoblasts and bone throughout life.  
 
Transcriptional Control of Osteoblast Differentiation 
Multiple transcription factors contribute to the regulation of osteoblast 
differentiation and function. To date, three such factors function in an osteoblast-
predominant manner: Runx2/Cbfa1 (Ducy, Zhang et al. 1997), Osterix (Osx) (Nakashima, 
Zhou et al. 2002), and Activating Transcription Factor 4 (ATF4)(Yang and Karsenty 2004; 
Yang, Matsuda et al. 2004).  
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Runx2 is a member of the Runt domain family of transcription factors. It is known 
to be the earliest and most powerful molecular determinant of osteoblast differentiation 
(Karsenty 2003). Runx2 is involved in the transcriptional activation of many promoters 
including those of Col1a1 and Osteocalcin (Banerjee, McCabe et al. 1997; Kern, Shen et 
al. 2001). Remarkably, Runx2-deficient mice have a cartilaginous skeleton without any 
osteoblasts(Komori, Yagi et al. 1997). Moreover, Runx2 is sufficient to induce osteoblast 
differentiation, and forced expression of Runx2 in skin fibroblasts leads to ectopic 
expression of osteocalcin, an osteoblast-specific gene. Similarly, the overexpression of 
Runx2 in odonotoblasts induces their transdifferentiation into osteoblasts, forming a 
bone structure (Miyazaki, Kanatani et al. 2008). However, it is notable that 
overexpression of Runx2 under the control of a 2.3-kb mouse Col1a1 promoter, which 
directs gene expression to immature and mature osteoblasts, does not increase bone 
mass, but rather induces osteopenia with multiple fractures. This phenotype is at least 
partially attributable to Runx2’s inhibition of osteoblast maturation and function, as 
demonstrated by the severe reduction of osteocalcin expression from both the bones 
and calvarial osteoblasts of the Runx2-overexpressing mice, and diminished number of 
terminally differentiated osteoblasts as well as osteocytes (Liu, Toyosawa et al. 2001; 
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Geoffroy, Kneissel et al. 2002; Kanatani, Fujita et al. 2006). Thus, Runx2 is required to 
direct multipotent mesenchymal cells to the osteoblast lineage and trigger the 
expression of major bone matrix proteins, leading to an increase in immature osteoblasts. 
However, Runx2 exerts inhibitory effects on osteoblast maturation.  
Osx is a zinc finger-containing transcription factor that is specifically expressed in 
osteoblasts. It is another transcription factor that is absolutely required for osteoblast 
differentiation, since inactivation of Osx also results in a complete absence of bone 
formation. The fact that Runx2 is normally expressed in Osx-null mice and that Osx is 
not expressed in Runx2-null mice indicates that Osx acts downstream of Runx2 
(Nakashima, Zhou et al. 2002). 
 
Activating Transcription Factor 4 
Activating transcription factor 4 (ATF4/CREB2) belongs to the ATF/CREB family of basic 
region-leucine zipper (bZip) transcription factors, and it activates gene transcription by 
forming homo/hetero-dimers and subsequently binding to the consensus cAMP 
responsive element (CRE) binding site (Hai and Curran 1991; Ameri and Harris 2008).  
The mouse ATF4 has 349 amino acids. It contains two leucine zipper motifs, zipper I 
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(aa304-339) and zipper II (aa90-125), which mediate interactions within ATF4s or with 
other partners. It also contains a basic region (aa270-303), responsible for DNA-binding 
activity (Fig. 2A) (Liang and Hai 1997).  
As an osteoblast specific transcription factor, ATF4 is important for osteoblast 
differentiation, osteogenesis, and terminal bone formation.  ATF4-deficient embryos 
display delayed skeletal development (Fig. 3A) and mice lacking ATF4 develop a severe 
low-bone-mass phenotype caused by decreased bone formation (Fig. 3B). ATF4’s 
function is at least partially transcriptional, since it binds directly to osteocalcin’s 
promoter at the OSE1 site and transactivate its expression (Fig. 4A & 4B) (Yang, 
Matsuda et al. 2004). As a result, bones from ATF4-null mice have lower expression of 
osteocalcin (Fig. 4C).  Conversely, ectopic expression of ATF4 in non-osteoblastic cells 
leads to overexpression of this osteoblast-specific gene (Fig. 4D) (Yang and Karsenty 
2004), and in vivo, transgenic mice overexpressing ATF4 in osteoblasts display a high-
bone-mass phenotype (Fig. 3C) (Elefteriou, Benson et al. 2006).  
Although no mutations in ATF4 have been directly reported in human skeletal 
dysplasia, the skeletal defects of two human genetic diseases, Coffin-Lowry syndrome 
(caused by inactivating mutation of Rsk2 gene) and a genetic disease resulting in cleft 
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Figure 2. Schematic illustration of ATF4 and Vimentin primary structures. A. 
Schematic illustration of ATF4 primary structure showing two leucine zipper domains at 
N and C termini (N-LZ and C-LZ) . Letter b represents basic amino acid-rich DNA 
binding domain. B. Schematic presentation of vimentin primary structure showing three 
putative leucine zippers (PLZ1-3) of vimentin.  
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Figure 3. Skeletal phenotypes in the absence of ATF4 or when ATF4 is 
overexpressed in osteoblasts. A. Alcian blue/alizarin red staining of E14 wt and Atf4-
deficient skeletons showing delayed skeletal development in absence of ATF4. B. 
Histomorphometric analysis of two-month-old wt and Atf4-deficient vertebrae, 
demonstrating the decrease in bone volume (BV/TV), trabeculae number (TbN), and 
trabecular thickness (TbTh) in Atf4-deficient mice. C. Histomorphometric analysis of two-
month-old wt and α1(I) collagen-Atf4 vertebrae, demonstrating the increase in bone 
volume (BV/TV), bone formation rate (BFR), and osteoblast surface (Ob.S/BS) in α1(I) 
collagen-Atf4 bones.  
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Figure 4. Osteocalcin Is a Target Gene of ATF4. A. Osteocalcin promoter (OG2) 
showing osteoblast specific element 2 (OSE2, Runx2 binding site) and osteoblast 
specific element 1(OSE1, ATF4 binding site) B. DNA cotransfection using pOG2-luc 
reporter and expression vectors of ATF4 in COS cells showing that ATF4 transactivates 
the Osteocalcin gene. C. Decreased Osteocalcin expression in Atf4-deficient bones. D. 
ATF4 accumulation by proteasome inhibitor MG115 induces endogenous Osteocalcin 
expression in NIH3T3 non-osteoblasts.  
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palate and low bone mass (caused by inactivating mutation of Satb2 gene), appear to be 
explained by a decrease in ATF4’s activity (Yang, Matsuda et al. 2004; Dobreva, 
Chahrour et al. 2006). In another disease, neurofibromatosis type I, the high-bone-mass 
phenotype is associated with an increase of ATF4’s activity (Elefteriou, Benson et al. 
2006). Together with the severe bone phenotype observed in Atf4-deficient mice, these 
studies illustrate the importance of ATF4 in bone biology. 
 
Regulation of ATF4 in the Context of Osteoblast Differentiation 
Given the importance of ATF4 during osteoblastogenesis, it is therefore not 
surprising that it should be regulated through several mechanisms. The expression and 
function of ATF4 are regulated mainly at a post-transcriptional level. This concept is best 
demonstrated by the observation that although Atf4 mRNA is ubiquitously expressed 
among different cell types and organs, its protein is restricted to osteoblasts, 
chondrocytes, and the eye (Yang and Karsenty 2004; Wang, Lian et al. 2009). In 
osteoblasts, this tissue-specific pattern was explained by a selective accumulation of the 
ATF4 protein, due to the lack of proteosomal degradation. Strikingly, ectopic expression 
of ATF4 protein in nonosteoblastic cells has been achieved with MG115, a proteasome 
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inhibitor, and functionally leads to Osteocalcin expression in these cells (Yang and 
Karsenty 2004).  
In addition to regulation of the proper abundance of ATF4 protein, its activity has 
also been shown to be subject to phosphorylation-based activation. As previously 
described, abnormal activity of ATF4 appears to be the cause of Coffin-Lowry syndrome 
(CLS). The molecule responsible for CLS, RSK2, is a growth factor-regulated kinase. It 
interacts with ATF4 directly and phosphorylates mouse ATF4 at serine 251, which 
subsequently activates ATF4. As a result, phosphorylation of ATF4 at serine 251 is not 
detectable in Rsk2-deficient cells, and similar to Atf4-deficient mice, both Rsk2-deficient 
and Rsk2+/-;Atf4+/- mice display low bone mass phenotypes (Yang, Matsuda et al. 2004). 
In addition, RSK2-independent phosphorylation and activation of ATF4 by protein kinase 
A (PKA) has also been observed at the serine 254 site in osteoblasts, favoring RANKL 
expression and subsequent osteoclast differentiation. Consequently, in Nf1-/- osteoblasts, 
where PKA activity is higher and ATF4 is more highly phosphorylated at serine 254, a 
PKA inhibitor H89 blunts the increase in RANKL expression (Elefteriou, Benson et al. 
2006).  
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Inhibitory factors of ATF4’s transactivation ability also exist in osteoblasts. One 
such factor is Factor Inhibiting ATF4-mediated Transcription (FIAT).  This leucine zipper 
nuclear molecule lacks a basic domain for DNA binding but interacts with ATF4 to 
repress its transcriptional activity. In vivo, overexpression of FIAT in osteoblasts leads to 
low osteocalcin expression and osteopenia, similar to the phenotype of Atf4-deficient 
mice (Yu, Ambartsoumian et al. 2005). These resports demonstrate that ATF4-mediated 
transcriptional control of osteoblast activity is a tightly regulated phenomenon and that 
protein-protein interactions play a critical role in the precise regulation of gene 
expression in bone-forming cells. 
 
Transforming Growth Factor β 
Transforming growth factor β (TGFβ) are cytokines that play important roles in 
several cellular functions such as proliferation, apoptosis, angiogenesis, wound healing, 
and bone formation (Massague 1998; Janssens, ten Dijke et al. 2005; Korpal and Kang 
2010).  The TGFβ family contains three closely related isoforms in mammals - TGFβ1, 
TGFβ2, and TGFβ3. TGFβ proteins, which are produced as latent dimers, can be 
activated by protease-mediated cleavage. Bioactive TGF-β then binds to a cell surface 
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receptor complex consisting of a pair of transmembrane serine/threonine kinases, TGFβ 
receptor type I (TβRI) and TGFβ receptor type II (TβRII), resulting in the phosphorylation 
and activation of TβRI kinase and consequent hierarchical phosphorylation events. 
In the canonical pathway, the signal is further propagated through 
phosphorylation of receptor-regulated Smad (Smad2/3) transcription factors at the SSXS 
motif in the C-terminal tail by the TβRI kinase (Abdollah, Macias-Silva et al. 1997; 
Souchelnytskyi, Tamaki et al. 1997). Once phosphorylated, Smad2/3 forms a 
heterodimeric complex with Smad4 (Co-Smad) and associates with additional DNA 
binding cofactors to turn on target genes (Massague 1998). 
Although the smads are critical mediators in the TGFβ signaling pathway, a substantial 
body of evidence illustrates the existence of additional, smad-independent pathways, 
known as non-canonical pathways. These pathways include various branches of MAP 
kinase (MAPK) pathways, Rho-like GTPase signaling pathways, and 
phosphatidylinositol-3-kinase (PI3K)/AKT pathways (for review, see (Zhang 2009)). PI3K 
is a heterodimer with a p85 regulatory subunit and p110 catalytic subunit. The p85 
subunit has two SH2 domains that bind to phospho-tyrosine with the consensus motif  
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Figure. 5. Simplified schematic representation of TGFβ signaling pathways. In the 
canonical pathway (left), TGFβ binds to the receptor TβRII (II), which recruits and 
phosphorylates TβRI (I), leading to activation of Smad2 and Smad3 by phosphorylation 
(P). Activated Smad2 and Smad3 form heterodimers with Smad4 and translocate to the 
nucleus. Together with co-activators, co-repressors and other transcription factors, the 
Smad complex regulates gene expression. Independent of the Smad2/3 activation, non-
canonical signalings also exist. As an example in the right, TGFβ can activate PI3K, 
possibly by inducing a physical interaction of its regulatory subunit. The activated PI3K 
then indirectly induces phosphorylation and activation of Akt, which in turn positively 
modulates mTOR function, resulting in the phosphorylation of S6K1 and consequent 
enhancement of cap-dependent translation.   
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(YXXM). This motif exists in many of the receptor tyrosine kinases and their substrates. 
Although the mechanism of TβRs-stimulated PI3K activity is still elusive, in a classical 
view of PI3K activation, the docking of PI3K in the vicinity of the plasma membrane 
through p85 recognition of the receptor phosphorylated YXXM activates the PI3K 
pathway. Once activated, PI3K converts PI-4,5-P2 (PIP2) into PI-3,4,5-P3 (PIP3), which 
localizes Akt to the membrane where it can be phosphorylated and activated by kinases 
such as phosphoinositide-dependent kinase-1 and 2 (PDK1 and PDK2) at two distinct 
redidues, Thr-308 and Ser-473 (Rameh and Cantley 1999).  The PI3K-dependent 
activation of Akt results in the phosphorylation and inhibition of the tumor suppressor 
proteins tuberous sclerosis 2 (TSC2), and the negative regulator of Ras-homolog 
enriched in brain (Rheb). The activation of Rheb therefore positively modulates mTOR 
function (Manning and Cantley 2003). mTOR in turn propagates the signals by 
phosphorylating two major targets: 4E-BP1 (first Thr37 and Thr46, then Thr70 and last 
Ser65) (Gingras, Gygi et al. 1999; Gingras, Raught et al. 2001) and S6K1 (Thr389), and 
eventually leads to dissociation of 4E-BP1 from eIF4E and S6K1from eIF3, respectively. 
Together these culminate in enhanced cap-dependent translation, particularly for many 
highly structured mRNAs, which are implicated in cell growth, proliferation and survival 
 17 
 
(Mamane, Petroulakis et al. 2004), corresponding for protein synthesis induced by TGFβ 
(Lamouille and Derynck 2007).  
 
TGFβ Signaling in Bone Biology 
The TGFβ family contains three closely related isoforms in mammals- TGFβ1, 
TGFβ2, and TGFβ3, and all three forms are detected in bone, with TGFβ1 being the 
most abundant (Hering, Isken et al. 2001). Numerous data from in vitro experiments 
have demonstrated the role of TGFβ1 in bone formation. Despite contrary results, most 
data agree with the following model. TGFβ recruits osteoblast progenitors (Lucas 1989; 
Pfeilschifter, Wolf et al. 1990) and stimulates their proliferation (Robey, Young et al. 
1987; Jian, Shen et al. 2006), thus expanding the pool of committed osteoblasts. On the 
other hand, it blocks the later stages of osteoblast differentiation, mineralization (Alliston, 
Choy et al. 2001; Maeda, Hayashi et al. 2004), apoptosis and transdifferentiation into 
osteocytes (Jilka, Weinstein et al. 1998; Karsdal, Larsen et al. 2002). The effect of TGFβ 
on osteoblast differentiation can be monitored by the expression of osteoblast 
differentiation markers, e.g., ALP and osteocalcin, both of which have been shown to be 
inhibited (Harris, Bonewald et al. 1994).  
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In the past decade, some of the molecular mechanisms underlying TGFβ actions 
in osteoblastogenesis have been elucidated at a transcriptional level. As previously 
mentioned, Runx2/Cbfa1 is a master regulator of osteoblast differentiation, and Runx2 
binding sites are found in the promoters of several bone formation markers including 
collagen 1, ALP, and Osteocalcin (Stein, Lian et al. 2004). TGFβ1 targets Runx2 through 
the phosphorylation of Smad3, which in turn physically interacts with Runx2 at Runx2-
responsive elements, resulting in repression of Runx2 and other osteogenic genes’ 
expression (Alliston, Choy et al. 2001).   Another molecule targeted by TGFβ, Fra-2, a 
Fos-related protein of the AP-1 family, is a novel positive regulator of bone and matrix 
formation, which binds to and transactivates the osteocalcin gene and collagen 1α2 
(Bozec, Bakiri et al. 2010). Treatment with TGFβ1 inhibits Fra-2’s activation of the 
osteocalcin gene via phosphorylation of Fra-2 (Banerjee, Stein et al. 1996). 
In addition, non-canonical TGFβ signaling has been suggested to play a role in 
regulating osteoblast differentiation. For example, one signaling pathway activated in 
response to TGFβ is the PI3K/Akt/mTOR pathway (Lamouille and Derynck 2007; Zhang 
2009). Suppression of PI3K and mTOR signaling using inhibitors such as wortmannin, 
rapamycin, and NVP-BEZ235 has been shown to promote osteogenesis in vitro, as 
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measured by an increase in mineral formation or bone nodule formation and an 
upregulation of genes involved in osteogenesis including osteocalcin (Ogawa, Tokuda et 
al. 1998; Kratchmarova, Blagoev et al. 2005; Fitter, Dewar et al. 2008; Lee, Yook et al. 
2010; Martin, Fitter et al. 2010). These observations suggest that TGFβ also regulates 
osteoblastogenesis in a Smad-independent manner.  
Information about the function of TGFβ in bone biology has also been gained 
from the study of mouse models, in which the levels of TGFβ signaling are manipulated 
when important players in this pathway are either eliminated/mutated by gene targeting 
or over-expressed in a tissue-specific manner. Given the broad application of the TGFβ 
signaling, it is not unexpected that deficiency of several intermediates of the pathway 
causes embryonic death, precluding any study of their effect on bone development. This 
includes TβRI, TβRII, Smad4, and Smad2 (Nomura and Li 1998; Sirard, de la Pompa et 
al. 1998; Weinstein, Yang et al. 1998; Larsson, Goumans et al. 2001). In accordance 
with the role of TGFβ in recruiting and stimulating the proliferation of osteoprogenitors, 
knocking out TGFβ1 results in decreased mineral content, accompanied by the absence 
of osteoblasts in trabecular bone (Geiser, Zeng et al. 1998; Atti, Gomez et al. 2002). 
TGFβ is believed to block the later stages of osteoblast differentiation, mineralization 
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(Alliston, Choy et al. 2001; Maeda, Hayashi et al. 2004), apoptosis and 
transdifferentiation into osteocytes (Jilka, Weinstein et al. 1998; Karsdal, Larsen et al. 
2002). Supporting this notion, loss of Smad3 was shown to result in osteopenia due to 
the inability of TGFβ to inhibit osteoblast differentiation, thereby increasing the osteocyte 
accumulation (Borton, Frederick et al. 2001). Furthermore, overexpression of TGFβ2 
under the osteocalcin promoter targeting mature osteoblasts leads to a dramatic loss of 
bone, together with increased osteoprogeniter cell numbers and impaired osteoblast 
differentiation (Erlebacher and Derynck 1996). Vice versa, a truncated TβRII driven by 
the osteocalcin promoter, which inhibits TGFβ signaling in mature but not early 
osteoblasts, results in an increase in trabecular bone mass (Filvaroff, Erlebacher et al. 
1999).  
 
TGFβ as a Therapeutic Target 
Although TGFβ appears to induce both positive and negative effects on bone 
cells, suppression of TGFβ signaling post-natally tends to generate similar anabolic 
effects. Several preclinical and clinical strategies for disrupting TGFβ signalling have 
been developed. Strategies such as preventing TGFβ ligand interaction with receptors 
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through the use of ligand traps, including neutralizing antibody and soluble TβRII/III 
receptors, reducing TGFβ translation by antisense-mediated technology, and reducing 
phosphorylation and activation of Smad proteins through TGFβ receptor kinase inhibitors 
have been applied in a preclinical and clinical settings. Edwards et al. have shown that 
4-week-treatment with 1D11, a TGFβ-neutralizing antibody blocking all three forms of 
TGFβ, increased BMD, trabecular thickness and Bone volume/Tissue volume, 
accompanied by elevated osteoblast numbers (Edwards, Nyman et al. 2010). Similarly, 
6-week-treatment with SD-208, a TβRI kinase inhibitor, increased bone mass, trabecular 
bone volume, and mineral concentration of bone matrix, accompanied by increased 
osteoblast numbers and formation rate (Mohammad, Chen et al. 2009). These 
experimental outcomes indicate that therapies that reduce TGFβ signaling may have 
significant clinical benefit in the treatment of low-bone-mass disease.  
 
Vimentin 
Intermediate filaments, along with Microtubules and Microfilaments are the major 
components of the cytoskeleton. The name ‘intermediate filaments’ comes from their 
diameter (10-12 nm) being intermediate between that of Microtubules (25 nm) and 
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Microfilaments (7-10 nm). The integrated network by the three filament systems is 
responsible for the mechanical integrity of the cell and is critically involved in such 
processes as cell division, motility and plasticity. Other than the difference in size, 
intermediate filaments exhibit several unique features: firstly, intermediate filaments 
appear to be the most dynamic of the three filament types. In particular, reversible 
dissociation-association of intermediate filament dimers can occur along the entire 
filament length and not just at the two ends as in microtubules and microfilaments 
(Strelkov, Herrmann et al. 2003). Secondly, they are expressed in a highly regulated 
manner in terms of tissue and developmental stage specificity (Toivola, Tao et al. 2005). 
Thirdly, intermediate filament proteins such as lamins are also found in the cell nucleus, 
forming a meshwork of filaments on the inside of the nuclear membrane.  
Vimentin belongs to the type III intermediate filaments. It appears to regulate cell 
migration in many cell types. For example, vimentin deficient cells display reduced 
mechanical stability and motility in vitro (Eckes, Dogic et al. 1998), and vimentin 
knockout mice show an impaired ability to heal wounds in vivo (Eckes, Colucci-Guyon et 
al. 2000).  
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Vimentin is normally expressed in cells of mesenchymal origin, and particularly, 
in undifferentiated cells (Steinert and Roop 1988). In addition, vimentin can also be 
expressed in epithelial cells undergoing EMT, and is a widely recognized marker of the 
EMT-like phoentype. Furthermore, several studies have reported overexpression of 
vimentin in breast cancer (Kokkinos, Wafai et al. 2007). In particular, vimentin has been 
identified as a marker of basal-like breast cancer cells (Neve, Chin et al. 2006). Several 
factors have been documented as regulators for vimentin expression. These include 
platelet-derived growth factor (PDGF) and TGFβ which up-regulates vimentin mRNA 
levels (Ferrari, Battini et al. 1986; Wu, Zhang et al. 2007), and a transcriptional repressor, 
ZBP-89, which down-regulates vimentin mRNA (Wieczorek, Lin et al. 2000). In addition, 
administration of PTH decreased the de novo biosynthesis of vimentin (Lomri and Marie 
1990).  However, it is not known whether, and if yes, how, the gene expression pattern 
of vimentin during either differentiation or EMT functionally contributes to the 
corresponding cellular events. In vitro studies have suggested high binding affinity of 
vimentin to a variety of synthetic and natural nucleic acids (Hartig, Huang et al. 1997), 
and this DNA-binding mediates translocation of vimentin into the nucleus of cultured 
cells (Hartig, Shoeman et al. 1998). These experimental observations led to the 
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hypothesis that vimentin not only fulfills general cytoskeletal functions in the cytoplasm 
but also participates in DNA-based events taking place in the nuclear interior. 
Interestingly, upon computational analysis, Capetanaki et al. predicted molecular 
interactions between vimentin and several CREB transcription factor family members 
based on their structural similarities localized to the important leucine zipper domains 
capable of coiled-coil interactions (Capetanaki, Kuisk et al. 1990). However, these 
hypotheses need further investigation and confirmation in mammalian cells. 
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CHAPTER II 
 
VIMENTIN INHIBITS ATF4-MEDIATED OSTEOCALCIN TRANSCRIPTION AND 
OSTEOBLAST DIFFERENTIATION 
 
The work in this chapter was published in the Journal of Biological Chemistry in 
September, 2009 (Lian, Wang et al. 2009). The paper was a collaborative effort between 
the laboratories of Xiangli Yang and Florent Elefteriou.  
 
Introduction 
Activating transcription factor 4 (ATF4) is an osteoblast-enriched transcription 
factor that regulates osteocalcin transcription and osteoblast terminal differentiation. To 
identify functional partners of ATF4, we applied ROS17/2.8 osteoblast nuclear extracts 
and purified recombinant His-ATF4 onto a Ni+ affinity matrix chromatography column. 
Vimentin was identified by liquid chromatography-mass spectrometry. 
Coimmunoprecipitation and pulldown assays revealed that vimentin interacted with 
ATF4 with its first leucine zipper domain. DNA cotransfection and gel retardation 
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demonstrated that vimentin inhibited the transactivation activity of ATF4 on osteocalcin 
by preventing it to bind OSE1, the ATF4 binding site on the osteocalcin promoter. 
Northern hybridization revealed that vimentin was expressed at a high level in immature 
osteoblasts and a low level in fully differentiated osteoblasts. Down-regulation of 
vimentin by small interfering RNA induced endogenous osteocalcin transcription in 
immature osteoblasts. Conversely, ectopic overexpression of vimentin in osteoblasts 
inhibited osteoblast differentiation as shown by lower alkaline phosphatase activity, 
delayed mineralization, and decreased expression of osteoblast marker genes such as 
bone sialoprotein and osteocalcin. Together, our data uncover a novel mechanism 
whereby a cytoskeletal protein, vimentin, acts as a break on differentiation in immature 
osteoblasts by interacting with ATF4.  
Osteoblasts, the bone-forming cells, originate from mesenchymal stem cells. The 
differentiation of mesenchymal stem cells to osteoblasts is regulated by several 
osteoblast-specific transcription factors, including Runx2 (Banerjee, McCabe et al. 1997; 
Ducy, Zhang et al. 1997; Komori, Yagi et al. 1997; Mundlos, Otto et al. 1997), osterix 
(Nakashima, Zhou et al. 2002), and ATF4 (Yang and Karsenty 2004; Yang, Matsuda et 
al. 2004). ATF4 belongs to the CREB leucine zipper (LZ)-containing protein family and is 
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known to regulate gene transcription by binding specifically to the ATF consensus core 
sequence, TGACGTCA (Hai and Hartman 2001). In osteoblasts, ATF4 binds to 
osteoblast-specific element 1 (OSE1), found in osteocalcin gene 2 (Ducy and Karsenty 
1995; Schinke and Karsenty 1999). The importance of ATF4 in skeletal biology is 
demonstrated by the fact that deletion of Atf4 from the mouse genome results in a 
severe runt phenotype in addition to very low bone mass due to a failure of osteoblast 
terminal differentiation and synthesis of type I collagen, the main constituent of bone 
matrix proteins (Yang, Matsuda et al. 2004). ATF4 transcriptional activity can be 
enhanced by posttranslational modifications such as phosphorylation by RSK2 and 
suppressed by interacting with other proteins such as FIAT (Yang, Matsuda et al. 2004; 
Yu, Ambartsoumian et al. 2005).  
Vimentin is a type III intermediate filament (IF) protein. IFs along with 
microtubules and actin microfilaments make up the dynamic cytoskeleton that maintains 
cell shape, enables intracellular transport, and supports cell division (Steinert and Liem 
1990; Herrmann and Aebi 2004; Ivaska, Pallari et al. 2007). Similar to other IF proteins, 
vimentin is expressed in a cell type- and developmental stage-specific manner. Vimentin 
is often expressed in undifferentiated and proliferative cells of mesenchymal origin and is 
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eventually replaced with cell type-specific IF subunits upon differentiation (Tapscott, 
Bennett et al. 1981; Capetanaki, Ngai et al. 1984). Studies using ras-transformed cells 
(Olson and Capetanaki 1989) and transgenic mouse models (Capetanaki, Smith et al. 
1989) have shown that vimentin regulates cell growth and differentiation. Recent studies 
using vimentin-deficient (Vim−/−) mice have revealed that loss of vimentin leads to 
failures in vascular adaptation resulting in pathological conditions, such as reduction of 
renal mass (Terzi, Henrion et al. 1997), malformation of glia cells (Colucci-Guyon, 
Gimenez et al. 1999), impairment of wound healing (Eckes, Colucci-Guyon et al. 2000), 
reduced resistance of arteries to shear stress (Henrion, Terzi et al. 1997), and 
disturbance of leukocytes homing to lymph nodes (Nieminen, Henttinen et al. 2006). 
However, the molecular mechanisms whereby vimentin regulates cell differentiation 
remain elusive.  
Here, we show evidence that vimentin interacts directly with ATF4 and prevents 
its transcriptional activity, thereby inhibiting its function in osteoblast differentiation. The 
inverse correlation between the expression patterns of vimentin and osteocalcin, a 
downstream target of ATF4, during osteoblast differentiation suggests that a decline in 
vimentin expression may be a prerequisite to the process of osteoblast differentiation.  
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Methods 
 
Materials 
Tissue culture medium and fetal bovine serum were purchased from Invitrogen. 
Restriction endonucleases and other DNA-modifying enzymes were purchased from 
either New England BioLabs or Promega. Radiolabeled nucleotides were obtained from 
PerkinElmer Life Sciences. Monoclonal anti-vimentin and antibodies against ATF4 (C20) 
were from Santa Cruz Biotechnology. All chemicals except for the indicated ones were 
from Sigma.  
 
Cell Culture 
COS1 monkey kidney cell and mouse osteoblastic MC3T3-E1 cell lines were 
cultured in Dulbecco's modified Eagle's medium and α-minimal essential medium, 
respectively. ROS17/2.8 rat osteoblastic cells were grown in Dulbecco's modified 
Eagle's medium/F-12 medium. All media were supplemented with 10% fetal bovine 
serum and 1% penicillin-streptomycin.  
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His-tagged ATF4 and GST-Vimentin Protein Purification 
Bacterially expressed His-tagged ATF4 protein was purified according to the 
method developed by Novagen. GST-vimentin protein was purified as described (Yang, 
Ji et al. 2000).  
 
Pulldown Experiment 
Nuclear extracts (NEs, 1 mg) isolated from ROS17/2.8 rat osteoblastic cells were 
incubated with or without His-ATF4 (10 μg) for 30 min at 4 °C and were loaded onto 
Ni2+-chelating Sepharose columns. After washing, proteins were eluted and resolved in 
4–20% gradient SDS-PAGE and visualized by Coomassie Blue staining. Individual 
proteins of interest were excised and subjected to trypsin digestion and identified by 
liquid chromatography and mass spectrometry (LC-MS).  
For mapping ATF4 binding domains of vimentin, 1 μg of purified GST-vimentin 
fusion protein, its variants, or GST (negative control) was incubated with glutathione-
Sepharose beads in phosphate-buffered saline buffer (PBS, pH 7.4) at 4 °C with rotation 
for 1 h and washed three times with PBS buffer, pH 7.4. The beads were then incubated 
with His-ATF4 at 4 °C for 2 h followed by three washes with PBS, pH 7.4. Bound 
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proteins were eluted by boiling for 5 min in 2× SDS sample buffer, separated by SDS-
PAGE, and stained with Coomassie Brilliant Blue.  
Similar methods were used to map vimentin binding domains of ATF4, except 1 
μg of purified His-ATF4 or truncated variants was incubated with Ni-NTA-agarose 
(Qiagen) in PBS, pH 8.0, containing 10 mM imidazole at 4 °C with rotation for 1 h and 
then washed three times with PBS containing 15 mM imidazole. GST-vimentin was then 
added and incubated with rotation for 2 h at 4 °C after washing three times with PBS 
containing 50 mM imidazole.  
 
NE Preparation 
Nuclear extracts of osteoblastic cells were isolated essentially according to the 
methods described (Dignam, Lebovitz et al. 1983; Schinke and Karsenty 1999).  
 
Vimentin Subcellular Localization 
MC3T3-E1 cells were transiently transfected with vectors expressing GFP-
vimentin or GFP alone. Cells were then fixed 48 h after transfection in 2% 
paraformaldehyde for 20 min at room temperature, permeabilized with 0.5% Triton X-
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100 for 5 min, and stained with DAPI to visualize nuclei. Images were taken with an 
Olympus BX41 fluorescence microscope with filters for GFP and DAPI.  
 
Immunoprecipitation 
COS1 cells (85% confluent) in 10-cm plates were transfected with 8 μg of FLAG-
ATF4, 6 μg of HA-vimentin, or both using Lipofectamine (Invitrogen). Cells were treated 
with 25 μM MG115 to stabilize ATF4 for 5 h before harvesting (Yang and Karsenty 2004). 
Isolated NEs (500 μg) were immunoprecipitated with 5 μl of anti-FLAG M2 beads (Sigma) 
or anti-HA beads (Abcam) for 8 h at 4 °C. After washing three times with ice-cold Tris-
buffered saline (50 mM Tris, 150 mM NaCl, pH 7.4), immunocomplexes and NEs (50 μl) 
as input controls were resolved by SDS-PAGE, transferred onto nitrocellulose 
membranes, and revealed by Western blotting using anti-FLAG M2 (Sigma) or anti-HA 
(Abcam) antibodies.  
 
Plasmids 
Mouse vimentin cDNA was amplified by reverse transcription-PCR using bone 
cDNA as template and cloned in pcDNA3.1+ mammalian expression vector (Invitrogen), 
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pEGFP-C1 expression vector (Clontech), or pGEX-4T1 bacterial expression vector 
(Amersham Biosciences). Three different truncation forms of mouse vimentin cDNA, 
named Vim1 (containing amino acids 1–155), Vim2 (containing amino acids 205–254), 
and Vim3 (containing amino acids 314–438), respectively, were PCR-amplified, flanked 
with cloning sites EcoRI and SalI, and inserted into mammalian expression vector 
pCMV-HA (Clontech) and bacterial expression vector pGEX-4T2. Mouse ATF4 cDNAs 
were subcloned into pCMV6CFLAG (Sigma) from a mammalian expression vector 
pCMV5/ATF4 (Yang, Matsuda et al. 2004). The integrity of all cDNA and production of 
the fusion protein were confirmed by DNA sequencing and Western blotting, respectively.  
 
DNA Transfection and Luciferase Assay 
COS1 cells were seeded at a density of 5 × 104/well in 24-well plates and 
transfected with 0.2 μg of the reporter plasmid (6OSE1-Luc or 3AP1-Luc), 0.05 μg of β-
galactosidase, 0.2 μg of transcription factor plasmid (FLAG-ATF4 or FosB) with or 
without 0.2 μg of pcDNA3.1-vimentin using Lipofectamine. Cells were lysed 24 h later, 
and the luciferase activity was normalized to the β-galactosidase activity.  
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Short Hairpin RNAs and Transfection 
Short hairpin RNAs targeting mouse Vim construct were cloned by ligating 
annealed oligonucleotides 5′-
ACCTCAAACGAGTACCGGAGACAGGTtcaagagACCTGTCTCCGGTACTCGTTTTT-3′ 
into a BbsI/BbsI-digested psiRNA-hH1neo G2 vector (InvivoGen, San Diego, CA). 2T3 
cells (2 × 105 cells/well in 6-well plates) were transfected with 1.5 μg of the reporter 
plasmid, 1.5 μg of siRNA-control or siRNA-Vim, and 0.2 μg of β-galactosidase plasmid). 
Cells were lysed 48 h later, and the luciferase activity was normalized to the β-
galactosidase activity. Total RNA was collected 48 h after transfection for Northern blot 
analysis.  
 
Electrophoretic Mobility Shift Assays (EMSAs) 
ROS17/2.8 NEs or His-ATF4 and increasing amounts of GST-vimentin, its 
deletion variants, or GST were incubated with 5 pmol of a radiolabeled double-stranded 
OSE1 oligonucleotide (Ducy and Karsenty 1995) at room temperature for 10 min. EMSA 
was performed as described (Schinke and Karsenty 1999).  
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Establishment of Permanent Cell Lines 
MC3T3-E1 cells (106 cells/10-cm dish) were transfected with 5 μg of pcDNA3.1 
vector or pcDNA3.1-vimentin. Cells were trypsinized and replated in α-minimal essential 
medium containing 10% fetal bovine serum, and 400 μg/ml G418 was added 2 days 
after transfection followed by 2-week selection. The expression of vimentin was 
confirmed by Northern blot analysis using the bovine growth hormone poly(A)+ as a 
probe.  
 
Northern Blot Analysis 
Total RNA from different adult mouse tissues, MC3T3-E1 cells, primary calvarial 
osteoblasts, or bone marrow stromal cells was isolated using TRIzol (Invitrogen) 
according to the manufacturer's protocols. Total RNA (5 μg) was resolved in 1% agarose 
gel, transferred onto nylon membranes. The membrane was cross-linked by UV light and 
hybridized following standard protocols with the indicated cDNA probes described 
previously (Yang and Karsenty 2004; Yang, Matsuda et al. 2004) except for vimentin 
cDNA (nucleotides 792–1218), which was cloned in this study (see Plasmids above for 
cloning strategies).  
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Osteoblast Differentiation Assays 
Confluent (d0) MC3T3-E1 in 12-well plates overexpressing vector (control) or 
vimentin were grown in G418-containing medium supplemented with 5 mM β-
glycerophosphate and 100 μg/ml ascorbic acid for 2, 4, 6, 12, or 20 days. Alkaline 
phosphatase activity was measured, and mineralization of osteoblasts was assayed by 
von Kossa staining as described (Yang, Ji et al. 2000).  
 
Statistics 
Data are expressed as mean ± S.D. Statistical analysis was performed using an 
unpaired t test.  
 
Results 
 
Identification of Vimentin as a potential ATF4-interactor 
To identify ATF4-interacting proteins in osteoblasts, we used a biochemical 
approach with nuclear extracts from ROS17/2.8 rat osteoblasts and His-tagged ATF4. 
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ATF4 was tagged with 6 histidines at its N terminus and expressed in bacteria to obtain 
large quantities of protein. Purified His-ATF4 was then incubated with nuclear extracts 
isolated from ROS17/2.8 rat osteoblasts, and the mixture was applied to a Ni-NTA 
column. After repeated washing, the ATF4-bound proteins were eluted, and elution 
fractions were resolved in a gradient SDS-PAGE. Slices containing a single protein band 
were subjected to trypsin digestion and LC-MS analysis. Among the specific ATF4-
bound proteins identified in the LC-MS analysis, one 37 kDa band was revealed as 
vimentin, a type III intermediate filament protein (Fig.6 , A and B).  
Vimentin is a cytoskeletal protein that has been well recognized as a protein 
localized in the cytoplasm and perinucleus, although it can be transported into the 
nucleus by DNA oligonucleotide mediation (26). The fact that it was pulled out from 
osteoblast nuclear extracts supported the nuclear localization of vimentin. To confirm 
this notion, we made GFP-vimentin fusion expression vector and introduced it into 
MC3T3-E1 cells. Our results showed that GFP-vimentin was present predominantly in 
the nucleus of a subset of GFP-positive cells, but GFP alone was distributed evenly in 
both nucleus and cytoplasm of all the GFP-positive cells (Fig. 6C).  
 
 38 
 
Vimentin interacts with ATF4 
Pulldown assays using either purified GST-vimentin or GST alone showed that 
ATF4 bound to GST-vimentin but not to the GST control (Fig. 7A). Conversely, vimentin 
bound to His-tagged ATF4 but not to Ni-NTA-agarose beads (Fig. 7B), confirming a 
direct interaction between vimentin and ATF4 in vitro. Reciprocal immunoprecipitation 
assays using nuclear extracts of COS1 cells transfected with HA-vimentin and/or FLAG-
ATF4 expression vectors revealed that vimentin interacted with ATF4 in cells as well 
because FLAG-ATF4-bound agarose beads precipitated HA-vimentin, and conversely, 
HA-vimentin precipitated FLAG-ATF4 (Fig. 7C). These results indicate that the 
interaction between vimentin and ATF4 is direct and specific in vitro and in cells.  
ATF4 has been predicted to form heterodimers preferentially through LZ domains 
(27), and it contains two LZ domains, namely N-LZ and C-LZ. The basic amino acid-rich 
DNA binding domain (b) is located close to C-LZ (Fig. 7D). Interestingly, we found three 
leucine-rich repeats within vimentin by visual examination of its primary structure and 
named them putative LZs (PLZ1 to PLZ3, Fig. 2E). To define which PLZ(s) mediated the 
interaction between vimentin and ATF4, we created three truncated variants of vimentin, 
Vim1, Vim2, and Vim3, which contained PLZ1, PLZ2, or PLZ3, respectively. We also 
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used three truncated variants of ATF4 described previously (Yang, Matsuda et al. 2004) 
that covered amino acids 1 to 151 (1–151, containing N-LZ), 110 to 221 (110–221), and 
186 to 349 (186–349, containing C-LZ), respectively, in the following experiments. 
Pulldown assays demonstrated that full-length vimentin or its truncated variant 
Vim1 bound strongly to full-length ATF4 (Fig. 7F). Full-length ATF4 and the two ATF4 
truncated variants, 1–151 and 186–349, interacted with full-length vimentin (Fig. 7G). 
From these results, we inferred that Vim1 binds the C-LZ domain of ATF4. Together, 
these results establish a novel interaction between a nuclear transcription factor, ATF4, 
and a cytoskeleton protein, vimentin.  
 
Vimentin Represses the Transactivation Activity of ATF4 
Osteocalcin expression is a hallmark of osteoblast terminal differentiation (Aubin, 
Liu et al. 1995). ATF4 was originally identified as one of the two main regulators of 
osteocalcin gene 2 transcription (Ducy and Karsenty 1995; Ducy, Zhang et al. 1997; 
Schinke, McKee et al. 1999; Yang, Matsuda et al. 2004). To understand the functional 
relevance of the vimentin-ATF4 interaction, we first tested whether vimentin affected the 
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transcriptional function of ATF4. Consistent with previous findings (Yang and Karsenty 
2004), ATF4 activated the p6OSE1-Luc reporter containing six copies of OSE1 (Ducy 
and Karsenty 1995; Schinke and Karsenty 1999) by about 50-fold in COS1 cells. This 
ATF4-dependent activation was inhibited by 70% when a vimentin expression vector 
was cotransfected (Fig. 8A). Similarly, vimentin inhibited ATF4-dependent activation of 
p160-Luc, a reporter construct containing a 160-bp native osteocalcin promoter, by 70%  
(Fig. 8B). The inhibition of ATF4-induced luciferase activity by vimentin was specific to 
ATF4 because vimentin did not affect the ability of FosB, another LZ-containing 
transcription factor, to activate a chimeric reporter gene containing three copies of AP1 
binding sites, pAP1-Luc (Fig. 8C). These data indicate that vimentin selectively 
represses the transactivation activity of ATF4.  
 
Vimentin Inhibits ATF4 Binding to Its Cognate DNA 
Two important observations prompted us to test whether vimentin inhibited 
ATF4-mediated transactivation of osteocalcin by interfering with the binding of ATF4 to 
its cognate DNA element. First, vimentin bound to the ATF4 C-LZ, the motif in proximity  
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Figure 6. Identification of vimentin. A, pulldown assay using His-ATF4 (ATF4, lane 1) 
as bait and NEs from ROS17/2.8 osteoblastic cells (lane 2) as pool of proteins. Proteins 
were separated with a 4–20% gradient SDS-PAGE and stained with Coomassie Brilliant 
Blue. A 37 kDa band (boxed) was excised and analyzed by MS. B, amino acid sequence 
of vimentin. MS analysis revealed peptides (bold letters) that covered 54% of vimentin. C, 
GFP-tagged vimentin (upper panel) transfected into MC3T3-E1 osteoblastic cells and 
analyzed for subcellular localization in comparison with GFP vector (lower panel) alone . 
Nuclei were visualized using DAPI staining (middle panel). Scale bar, 10 μm.  
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Figure 7. Vimentin (Vim) interacts with ATF4. A, pulldown assay showing that GST-
vimentin binds directly to ATF4. B, pulldown assay using His-ATF4 and Ni-NTA resin 
column showing that ATF4 binds directly to vimentin. C, reciprocal 
coimmunoprecipitation. NEs of COS cells transfected with HA-vimentin and/or FLAG-
ATF4 were immunoprecipitated with anti-HA or anti-FLAG antibody and visualized with 
anti-FLAG and anti-HA antibodies (top two panels). Total protein (10%) of each 
transfection served as loading control (bottom panel). D, schematic illustration of ATF4 
primary structure showing two LZ domains at N and C termini. Letter b represents basic 
amino acid-rich DNA binding domain. E, schematic presentation of vimentin primary 
structure showing three PLZs of vimentin. F, PLZ1 of vimentin interacting with ATF4. 
Pulldown assay was carried out using purified GST-vimentin and its truncated variants 
GST-Vim1–3 and His-ATF4. Note that only full-length vimentin (Vim-fl) or its variant 
containing the first PLZ interacted with His-ATF4. G, LZs of ATF4 interacting with 
vimentin. Pulldown assay was performed using purified His-ATF4 and its three indicated 
deletional variants. Note that full-length ATF4 (Full length) and both of its LZ-containing 
variants, 1–151 and 186–349, bound vimentin.  
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to the basic DNA binding domain (Fig. 6, D and G), which may create a steric barrier for 
ATF4 to access the DNA. Second, vimentin can be detected in the nucleus of many cell 
types, including osteoblasts (Fig. 6C) and epithelial cells (Monteiro, Hicks et al. 1994; 
Rogers, Eckelt et al. 1995). ATF4 binds OSE1 in the osteocalcin promoter in vitro and in 
vivo as demonstrated by EMSA and by the use of transgenic mice (Ducy and Karsenty 
1995; Schinke and Karsenty 1999; Yang and Karsenty 2004; Yang, Matsuda et al. 2004). 
Using a similar assay, we found that GST-vimentin inhibited His-ATF4 binding to OSE1 
dose-dependently. As a negative control and consistent with the pulldown assay results 
(Fig. 7A), GST alone did not have any effect on His-ATF4 binding to the OSE1 (Fig. 8D). 
Accordingly, GST-vimentin fusion protein but not GST alone inhibited endogenous ATF4 
binding to OSE1 in a dose-dependent manner (Fig. 8E).  
Given the mapping data that indicated that Vim1 was sufficient to mediate the 
interaction between vimentin and ATF4 (Fig. 7F), we tested whether Vim1 affected the 
transactivation activity of ATF4. DNA cotransfection using a Vim1 expression plasmid 
showed an inhibition of ATF4-dependent activation of 6OSE1-Luc reporter to an extent 
similar to that of full-length vimentin, whereas Vim2 or Vim3 had no effect (Fig. 8F). 
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Figure 8. Vimentin (Vim) inhibits ATF4-dependent transactivation of osteocalcin 
transcription by blocking its binding to OSE1. A–C, DNA cotransfections of COS1 
cells with reporter construct containing six copies of ATF4 binding site OSE1, p6OSE1-
Luc (A), a native osteocalcin promoter, p160-Luc (B), three copies of binding sites of 
AP1 family (C), and/or expression vectors of ATF4, FosB, and/or vimentin as indicated. 
Note that ATF4-induced but not FosB-induced luciferase activity was inhibited by more 
than 70% by vimentin. D, vimentin inhibiting the binding of ATF4 to OSE1. EMSA was 
performed using purified His-ATF4 and radiolabeled OSE1 as a probe. Note that 
vimentin inhibited ATF4 binding to OSE1 dose-dependently. E, EMSA showing that 
vimentin inhibits endogenous ATF4 (middle bands are ATF4·OSE1 complexes (9)) from 
ROS17/2.8 osteoblastic cells binding to OSE1. F, DNA cotransfection in COS1 cells with 
p6OSE1-Luc and expression vectors of FLAG-ATF4 and/or HA-Vim1, -Vim2, or -Vim3. 
G and H, EMSA. Note that GST-Vim1 inhibited His-ATF4 (G) or endogenous ATF4 (H) 
binding to OSE1 in a dose-dependent manner. The luciferase activities were normalized 
for the β-galactosidase activity and are presented as fold activation relative to the 
luciferase levels of the reporter construct alone. Values are the mean ± S.D. of three 
independent experiments. *, p < 0.01; **, p < 0.001; N.S., not significant.  
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Consistently, Vim1 but not Vim2 or Vim3 inhibited His-ATF4 or endogenous ATF4 
binding to OSE1 in a dose-dependent manner (Fig. 8, G and H). These data indicate 
that vimentin inhibits ATF4 transcriptional activity by affecting its binding to cognate DNA 
via the first PLZ domain of vimentin.  
Down-regulation of vimentin induces endogenous osteocalcin transcription 
To strengthen further our findings that vimentin inhibited the transcriptional 
activity of ATF4, we next tested whether knocking down endogenous vimentin in 
immature osteoblasts would conversely induce osteocalcin transcription. We thus 
constructed a vector expressing short hairpin RNA of vimentin (psiRNA-Vim) and 
introduced it into 2T3 mouse osteoblasts. Northern blot analysis demonstrated that 
endogenous vimentin mRNA was decreased in cells transfected with psiRNA-Vim. 
Supporting our hypothesis, endogenous osteocalcin mRNA was induced in cells 
depleted in vimentin by psiRNA-Vim (Fig. 9A). To confirm these expression data, we 
performed DNA cotransfection assays to determine whether vimentin depletion affected 
endogenous ATF4-dependent activation of luciferase activity driven by 6OSE1 
(p6OSE1-Luc) or native 160-bp osteocalcin promoter (p160-Luc). Our results revealed 
that psiRNA-Vim but not the empty psiRNA vector enhanced ATF4-induced luciferase 
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Figure 9.Down-regulation of vimentin by siRNA enhances osteocalcin expression. 
A–C, DNA cotransfections of 2T3 osteoblastic cells with reporter p6OSE1-Luc (A), p160-
Luc (B), AP1-Luc (C), and vectors of control (psiRNA) or vimentin (psiRNA-Vim). Note 
that vimentin siRNA induced activation of osteocalcin promoter by >2-fold. Values are 
the mean ± S.D. of three independent experiments. *, p < 0.01; N.S., not significant. D, 
Northern blot using total RNA from 2T3 osteoblasts transfected with control or siRNA 
against vimentin. Note that depletion of vimentin triggered osteocalcin expression. 
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA was used as a loading 
control.  
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activity 2.5-fold in both 6OSE1-Luc and p160-Luc reporter constructs (Fig. 9, B and C).  
This induction in luciferase activity was specific to endogenous ATF4 because psiRNA-
Vim did not significantly enhance the AP1-induced luciferase activity (Fig. 9D). Therefore, 
we conclude that vimentin acts as an inhibitor on endogenous osteocalcin transcription 
and thus as a break on the transactivation activity of ATF4.  
 
Vimentin delays osteoblast differentiation 
To address whether the inhibitory action of vimentin on the transactivation activity 
of ATF4 had any biological relevance and specifically regulated osteoblast differentiation, 
we created MC3T3-E1 mouse osteoblastic cells that stably expressed vimentin. Stable 
expression of vimentin was confirmed by Northern blot analysis (Fig. 10A). The 
progression of osteoblast differentiation was monitored by alkaline phosphatase assay, 
von Kossa staining of mineralized nodules, and the temporal expression of immature 
osteoblastic differentiation markers, such as type I collagen (Col1α1), and differentiated  
osteoblast markers, such as osteocalcin and bone sialoprotein (Bsp). In addition, the 
expression of Runx2 and osterix, another two important osteoblast differentiation factors, 
was also examined. MC3T3-E1 cells carrying empty vector responded to osteogenic 
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Figure 10. Vimentin delays osteoblast differentiation. A, overexpression of vimentin 
in MC3T3-E1 osteoblasts. Vimentin in pcDNA3.1 expression vector was stably 
expressed in the MC3T3-E1 osteoblastic cell line. Bovine growth hormone (BGH) was 
used to probe for exogenous vimentin. B, vimentin decreasing alkaline phosphatase 
(ALP) activity. Decreased alkaline phosphatase activity at 2 and 4 days after osteogenic 
induction was observed in MC3T3-E1 cells overexpressing vimentin compared with the 
controls. C, vimentin inhibiting mineralization of MC3T3-E1 cells. von Kossa staining was 
done at 6, 12, and 20 days after differentiation of control cells (Vector) and vimentin-
overexpressing cells. Cells were counterstained with acid fuchsin on day 0 before 
osteogenic differentiation induction showing that the same amount of cells were plated. 
D, Northern blot analysis showing the expression of osteocalcin (Ocn) and bone 
sialoprotein (Bsp), two mature osteoblast marker genes, and Col1α1, an early osteoblast 
marker, together with three transcription factors that are important for osteoblast 
differentiation, Runx2, osterix (Osx), and ATF4 (Atf4). Glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) mRNA was used as a loading control.  
 
 
 
 51 
 
 
 52 
 
induction as indicated by increasing alkaline phosphatase activity over time. This 
response was inhibited in cells overexpressing vimentin 2 and 4 days upon induction 
(Fig. 10B). As expected, 6 days after differentiation induction, mineralized nodules 
started to form in MC3T3-E1 cells that carried control empty vector. In contrast, no 
mineralized nodules were observed in day 6 cultures of MC3T3-E1 cells that 
overexpressed vimentin. The onset of mineralized nodule formation in vimentin-
expressing cells was only detected after 12 days of differentiation, and the number and 
size of mineralized nodules were still severely less after 20 days of differentiation 
compared with control cells (Fig. 10C).  
Consistent with the mineralization results, two marker genes for mature 
osteoblast, osteocalcin and Bsp, were expressed at day 6 after differentiation induction 
and increased over time in control MC3T3-E1 cells carrying empty vector. However, in 
cells that overexpressed vimentin, the mRNA levels of osteocalcin, Bsp, and osterix 
were not readily detectable at all-time points examined, including days 6, 12, and 20 
after differentiation induction, whereas the expression of Atf4, Col1α1, and Runx2 was 
not overly changed, especially if one takes into account of loading controls (Fig. 10D).  
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Figure 11. Expression pattern of vimentin (Vim) mRNA and protein. A, Northern blot 
analysis using total RNA from indicated mouse tissues showing that vimentin mRNA is 
highly expressed in bone. B–D. Northern blot using total RNA from MC3T3-E1 (B), 
primary calvarial osteoblasts (C), and primary bone marrow stromal cells (D) at the 
indicated times after differentiation induction. Note that vimentin mRNA is down-
regulated at day 10 or day 20 after osteoblast differentiation induction. Glyceraldehyde-
3-phosphate dehydrogenase (Gapdh) mRNA was used as a loading control. E, Western 
blot analysis using nuclear extracts of rat primary calvarial osteoblasts. Note that 
vimentin protein decreased during osteoblast differentiation. These results are 
representatives of three independent experiments. F, schematic illustration of the role of 
vimentin in osteoblast differentiation. In preosteoblasts, vimentin is highly expressed, 
and it inhibits osteocalcin transcription and premature osteoblast differentiation by 
binding to ATF4. Along with the progression of osteoblast differentiation, the vimentin 
level decreases, and thus the inhibition of ATF4 is released, osteocalcin transcription is 
then initiated, and osteoblast terminal differentiation is achieved.  
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From these results, we conclude that vimentin inhibits (i) endogenous osteocalcin 
transcription and (ii) osteoblast differentiation. The observation that vimentin inhibited the  
expression of mature osteoblast marker genes more dramatically than that of immature 
osteoblast marker genes was strikingly similar to what was seen in the Atf4−/− mice 
(Yang, Matsuda et al. 2004). This similarity strengthens our hypothesis that vimentin 
may execute its function in osteoblasts by affecting the function of ATF4.  
 
Vimentin expression pattern in the osteoblastic lineage 
To understand the physiological role of vimentin during osteoblast differentiation, 
we examined the expression pattern of vimentin in various mouse tissues, MC3T3-E1 
osteoblasts, primary calvarial cells, and bone marrow stromal osteoprogenitors that have 
the potential to differentiate into osteoblasts (Aubin 2001). Northern blot analysis showed 
that vimentin was highly expressed in vertebral bones, and it was the most abundant 
message RNA detected among all of the tissues examined (Fig. 11A). Interestingly, we 
found that the level of vimentin mRNA in MC3T3-E1 cells and primary calvarial 
osteoblasts decreased over time during the course of differentiation: high at the initiation 
of differentiation (day 0, Fig. 11, B and C), and low at the end of differentiation (day 10, 
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Fig. 11, B and C). Similarly, in alkaline phosphatase-positive mouse bone marrow 
stromal osteoprogenitors, vimentin mRNA was high at day 5 after differentiation 
induction, but low at day 20 after differentiation induction (Fig. 11D). Consistently, 
vimentin protein showed the same expression pattern as its mRNA in rat primary 
osteoblasts (Fig. 11E). Collectively, these results suggest that down-regulation of 
vimentin during osteoblast differentiation may be a required mechanism to relieve its 
inhibition of ATF4 transcriptional activity and to promote osteoblast terminal 
differentiation (Fig. 11F).  
 
Discussion 
In summary, this study identified a novel interaction between vimentin and ATF4. 
To our knowledge, our work revealed for the first time a direct interaction between an 
intermediate filament protein and a transcription factor. The experimental data establish 
that through its interaction with ATF4, vimentin prevents the binding of ATF4 to its target 
DNA and thus leads to delayed osteoblast differentiation. Consistent with its inhibitory 
role, vimentin expression is progressively decreased at both mRNA and protein levels 
during the course of osteoblast differentiation, whereas the expression of osteocalcin, a 
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transcriptional target gene of ATF4, progressively increases. This piece of evidence 
suggests that at an early stage of osteoblast differentiation, the transcriptional activity of 
ATF4 is repressed by vimentin, which explains why osteocalcin transcription does not 
occur in these cells. This hypothesis is supported by the observation that ATF4 binds to 
osteocalcin promoter at day 8 but not at day 0 of differentiation in primary osteoblasts 
(Yu, Akhouayri et al. 2009). Therefore, removal of vimentin-mediated inhibition is a 
prerequisite for preosteoblasts to differentiate into terminal osteoblasts.  
Our study has also defined that the PLZ domains of vimentin mediate the 
interaction between vimentin and ATF4. The sequence and structural similarities 
between the leucine-rich repeats of vimentin and the LZ motif of several other LZ-
containing nuclear regulators belonging to the CREB family, such as CREB, Fos, and 
Jun, have been described previously. Based on computational analysis, the authors 
predicted the existence of molecular interactions between vimentin and these nuclear 
regulators through their similar leucine-rich amphipathic helices (Capetanaki, Kuisk et al. 
1990). Our mapping data have now provided experimental evidence supporting these 
predictions, although only one of such putative LZ motifs in vimentin was shown to be 
responsible for this interaction. The biological significance of this association is 
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supported by evidence demonstrating that the PLZ1 of vimentin behaves identically to 
the full-length protein to inhibit ATF4 binding and activation of the osteocalcin promoter. 
Therefore, this provides insights into the possibility that small molecules could be 
screened for their ability to block the binding of vimentin to ATF4 and to stimulate 
osteoblast terminal differentiation and function.  
It is not understood at present whether the interaction between vimentin and 
ATF4 takes place in the nucleus or the cytoplasm. Several observations strongly 
suggest that vimentin, despite its well-known cytoplasmic location, interacts with ATF4 
within the nucleus. First, vimentin inhibits ATF4 to bind its cognate DNA. Second, 
vimentin was pulled out from ROS28/1.7 osteoblast nuclear extracts and recognized by 
an anti-vimentin antibody in Western blotting in the nuclear extracts of primary calvarial 
osteoblasts. Third, GST-vimentin was detected in the nucleus of MC3T3-E1 osteoblasts 
(Fig. 6C). Supporting this, vimentin was observed independently in the nucleus of 
nonosteoblastic cells (Rogers, Eckelt et al. 1995) and osteoblasts (Monteiro, Hicks et al. 
1994). Interestingly, vimentin can be modified by phosphorylation, leading to the 
generation of a 50-kDa truncated vimentin (Singh and Arlinghaus 1989), the same 
molecular mass as vimentin observed in rat osteoblasts (Fig. 11E). It is unknown 
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whether ATF4 binds to monomeric or polymeric forms of vimentin, which of these forms 
is present within the nucleus, and whether such interactions dictate the inhibitory and 
nuclear function of vimentin. Further studies are needed to elucidate these mechanisms.  
Although less dramatically, vimentin overexpression also caused a decrease in the 
expression of some marker genes for immature osteoblasts, particularly osterix and 
Runx2, two important osteoblast differentiation factors (Ducy, Zhang et al. 1997; Komori, 
Yagi et al. 1997; Mundlos, Otto et al. 1997; Nakashima, Zhou et al. 2002). This result is 
interesting because it suggests that vimentin may also inhibit the function of osterix and 
Runx2 in the regulation of osteoblast differentiation. However, whether this effect is via a 
direct interaction between vimentin and Runx2 or osterix through domains other than the 
leucine-rich repeats, or via other indirect actions remains to be determined.  
Based on our data, we speculate that the disappearance of vimentin in 
osteoblasts allows the progression of immature osteoblasts to fully differentiated and 
functional osteoblasts. One may wonder why there is such a need for several inhibitors 
of differentiation in the osteoblasts. One plausible explanation is that such inhibitors are 
important for the prevention of premature differentiation of osteoblasts, allowing for a 
sufficient pool of preosteoblasts with the proliferative potential to be maintained at the 
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site of bone formation, in response to extracellular cues. Interestingly, some extracellular 
cues, such as parathyroid hormone (Lomri and Marie 1988) and transforming growth 
factor (Lomri and Marie 1990), regulate de novo synthesis of vimentin in osteoblasts. 
However, it is unknown whether this regulation is temporal or dependent on 
differentiation progression. Further studies are needed to identify molecules involved in 
the regulation of vimentin expression in osteoblasts.  
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CHAPTER III 
 
TGF-BETA-INDUCED REPRESSION OF ATF4 BY VIMENTIN DECREASES 
OSTEOCALCIN EXPRESSION AND INHIBITS OSTEOBLAST DIFFERENTIATION. 
 
Introduction 
Maintenance of osteoblast progenitors and their differentiation are highly 
synchronized events that are controlled by extracellular clues. TGFβ is a bone-enriched 
extracellular growth hormone that plays important roles in bone, and it functions through 
supporting osteoblast progenitors (James, Levine et al. 2005; Vallier, Alexander et al. 
2005; Watabe and Miyazono 2009) while inhibiting terminal differentiation (Centrella, 
Horowitz et al. 1994; Maeda, Hayashi et al. 2004).  
Extracellular signaling factors can exert their functions through regulating 
transcriptional factors which directly control the on and off of tissue/cell-specific genes 
(Alliston, Choy et al. 2001; Liu, Black et al. 2001; Liu, Kang et al. 2004). Several 
osteoblast specific transcription factors have been identified in the past decades, 
including Runx2, osterix, and ATF4, the absence of which leads to poor or even failed 
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osteoblast differentiation and bone formation (Ducy, Zhang et al. 1997; Komori, Yagi et 
al. 1997; Otto, Thornell et al. 1997; Nakashima, Zhou et al. 2002; Yang, Matsuda et al. 
2004).  As an osteoblast specific transcription factor, ATF4 is important for osteoblast 
differentiation, osteogenesis, and terminal bone formation.  Mutation of ATF4 leads to 
low bone mass, which is accompanied by low expression of osteoblast-specific genes, 
including osteocalcin.  ATF4’s function is at least partially transcriptional, since it binds 
directly to osteocalcin’s promoter at the OSE1 site and transactivates its expression 
(Yang, Matsuda et al. 2004).  In addition, ectopic expression of ATF4 in non-osteoblastic 
cells leads to overexpression of this osteoblast-specific gene’s expression (Yang and 
Karsenty 2004). 
Direct regulation of ATF4 has been demonstrated through many ATF4 interactors, 
such as RSK2, PKA, FIAT, STAB2, and Vimentin, and several of them have been shown 
to further have an effect on osteoblast differentiation and/or bone formation (Yang, 
Matsuda et al. 2004; Yu, Ambartsoumian et al. 2005; Dobreva, Chahrour et al. 2006; 
Elefteriou, Benson et al. 2006; Lian, Wang et al. 2009) . We previously demonstrated the 
interaction between vimentin and ATF4. Through binding with ATF4 at its leucine zipper 
domain, vimentin inhibits ATF4’s transcriptional activity on osteocalcin gene expression. 
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Overexpression of vimentin leads to a delay in osteoblast differentiation and low 
expression of endogenous level of osteocalcin. Conversely, down-regulation of vimentin 
leads to up-regulation of endogenous osteocalcin gene expression (Lian, Wang et al. 
2009). 
Vimentin has been shown to be up-regulated by TGFβ in several biological 
conditions such as EMT and cancer progression, with the functional relevance not clear 
to date (Margetts, Bonniaud et al. 2005). In this paper we show for the first time that 
TGFβ up-regulates vimentin in osteoblasts through a non-canonical TGFβ pathway 
resulting in vimentin protein synthesis, which mediates the inhibitory effect of TGFβ on 
osteoblast differentiation. TGFβ inhibits the endogenous as well as the ATF4-mediated 
osteocalcin expression, and these inhibitions were abolished when vimentin was 
targeted by siRNA knockdown. ATF4 is an important target of TGFβ since osteoblasts 
lacking ATF4 are less or even un-responsive to TGFβ signaling as compared to wild-
type osteoblasts in terms of ALP activity, osteocalcin expression, and bone nodule 
mineralization. Although blocking TGFβ signaling in vivo with 2G7 antibody can elevate 
bone mass, this effect was not observed in Atf4-deficient mice.  Our findings revealed a 
new mechanism whereby TGFβ, through a non-canonical pathway, upregulates vimentin, 
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which in turn inhibits ATF4’s transcriptional activity as well as osteoblast differentiation 
and bone formation. 
 
Methods 
Materials 
Tissue culture medium and fetal bovine serum were purchased from Invitrogen. 
Anti-Vim antibodies were from Santa Cruz Biotechnology (V9, against rat Vim) and 
Biovision (#3634, against mouse Vim). Antibodies against ATF4 (C20) and Sp1 (PEP2) 
were from Santa Cruz Biotechnology, against HA-tag from Abcam (ab9110), against 
Flag from Sigma (M2), and against phospho-Smad2 (#3101) from Cell Signaling. 
Recombinant human TGF-β1 was from R&D systems.  All chemicals except for the 
indicated ones were from Sigma.  
 
Northern blot analysis and real time RT-PCR 
Total RNA from adult mouse long bones, primary calvarial osteoblasts, 2T3 cells, 
or bone marrow stromal cells was isolated using TRIzol (Invitrogen) according to the 
manufacturer's protocols. 5 μg total RNA was resolved in 1% agarose gel and 
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transferred onto nylon membranes. The membrane was cross-linked by UV light and 
hybridized following standard protocols with the indicated cDNA probes described 
previously (Lian, Wang et al. 2009). Real time RT-PCR was performed using a standard 
TaqMan or SYBR Green PCR Kit protocol on an Applied Biosystems 7300 machine. 
After treatment with DNase I, total RNA (2 μg) was reverse-transcribed with reverse 
transcriptase (Invitrogen) using 100 μM random hexamer primers. Specific 
oligonucleotide primers were either synthesized for SYBR Green (Ocn, forward 
CTACAAACGCATCTACGGTATCAC and reverse AGA GAGGACAGGGAGGATCAAG) 
or from Applied Biosystems for TaqMan system (Gapdh, 4352339E, RefSeq: 
NM_008084.2). 
 
Immunofluorescence 
ROS17/2.8 cells were grown on 4-well cultureslides for 16 h until reaching sub-
confluence, washed with PBS, and fixed with Methanol for 20 min at -20 °C. Cells were 
then permeabilised and blocked with 5%BSA with 0.2% Triton X-100 in PBS for 30 min, 
and incubated with the respective primary antibody in 2% BSA overnight at 4°C. ATF4 
proteins were stained with 1 μg/ml polyclonal anti-ATF4 antibody (C-20, Santa Cruz) and 
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Vim proteins were stained with 0.5 μg/ml monoclonal anti-Vim antibody (V9, Santa Cruz). 
After PBS-washing, cells were incubated with cy3-conjugated sheep anti-mouse or 
FITC-conjugated goat-anti-rabbit secondary antibody for 1 h at RT. After washing, cells 
were counter-stained with DAPI, washed briefly, and mounted in Aqua-Poly Mounting 
solution (Polysciences). 
 
Pharmacological treatments 
ROS17/2.8 cells or primary calvarial osteoblasts were grown on 60mm plates 
until 90% confluent and then incubated in serum free medium overnight. For TGFβ1 
treatment, DMSO, SB505124 (Sigma), cycloheximide (Sigma), Wortmannin 
(EMD4Biosciences), or Rapamycin (EMD4Biosciences) were pre-incubated with cells for 
30-60 min before addition of TGFβ1 or vehicle (4mM HCl with 1 mg/ml BSA). For whole 
cell lysate (WCL) and nuclear extracts (NE) collection, cells were collected 45 min or 4 
hrs following TGFβ1 treatment. For luciferase assay, cells were lysed 6 hours post 
TGFβ1 treatment.  
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Transfection and Luciferase assay 
Cells were seeded at a density of 2.5 × 104/cm2 for 20 hrs and transfected with 
0.6 μg/ml of each indicated reporter plasmid (p6xOSE1-Luc, p6xmOSE1-Luc, or 
p3xAP1-Luc) together with 0.06 μg/ml of β-galactosidase,  mammalian  expression 
plasmid (FLAG-ATF4, FosB, or HA-Vim), or psiRNA plasmids (psiRNA vector or 
psiRNA-Vim) using Lipofectamine. Cells were lysed 24 hrs later, and the luciferase 
activity was measured and normalized to the β-galactosidase activity as described (Lian, 
Wang et al. 2009). 
 
Microcomputed tomography (µCT) analysis 
Femur samples were collected and fixed overnight in 4% PFA (pH 7.4) and then 
70% ethanol. Trabecular bone were evaluated using a μCT imaging system (Scanco 
μCT 40; Scanco Medical, Bassersdorf, Switzerland). The femur was fit into the specimen 
tube aligned with scanning axis. Tomographic images were acquired at 55kV and 145 
mA with an isotropic voxel size of 12μm, and at an integration time of 250 ms with 500 
projections collected per 180 degree rotation. For 100 slices distal to the growth plate, 
contours were fit to the inner layer of the cortical bone. Applying the threshold of 300 mg 
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hydroxyapatite/cm3 to each femur, volume of trabecular bone tissue (TV), trabecular 
bone volume (BV) as well as volumetric density (in mgHA/cm3) of the mineralized tissue 
(BMD) were measured as fraction of mineralized tissue within the trabecular bone.  
 
Osteoblast differentiation, ALP assay, von Kossa assay 
Confluent (D0) primary calvarial osteoblasts in 24-well plates were grown in 
αMEM supplemented with 5 mM β-glycerophosphate and 100 μg/ml ascorbic acid for 2 
days followed by Alkaline phosphatase staining, 12 days subject to von Kossa staining 
and RNA isolation as described (Lian, Wang et al. 2009). 
 
TGFβ neutralizing antibody treatment regimen 
10-week-old WT and Atf4-/- mice (n>5) were treated with 10mg/kg of 2G7 or 
control IgG 3 times per week for 4 weeks by sterile intra-peritoneal injection.  
 
Statistics 
Data are expressed as mean ± S.D. Statistical analysis was performed using an 
unpaired t test except for the 2G7 study, where paired t test was used. 
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Results 
 
TGFβ inhibits ATF4-mediated Osteocalcin expression.  
As an inhibitor of osteoblast terminal differentiation, TGFβ prevents expression of 
osteoblast-specific genes such as osteocalcin ((Centrella, Horowitz et al. 1994), Fig.12A). 
The suppression of Osteocalcin expression by TGFβ is similar to what is observed in 
Atf4-/- bone, and furthermore, ATF4 has been shown to be one of the transcription 
factors activating osteocalcin expression (Yang, Matsuda et al. 2004). These 
observations open the possibility that TGFβ may inhibit osteoblast differentiation through 
suppressing ATF4. A luciferase construct driven by 6 copies of OSE1 (p6xOSE1-luc) 
has been shown to be specifically activated by ATF4 (Yang, Matsuda et al. 2004); this 
approach allowed us to test specifically if TGFβ targets ATF4. We therefore transfected 
p6xOSE1-luc into ROS17/2.8 cells as a specific indicator of ATF4’s transcriptional 
activity and treated these cells with increasing amount of TGFβ1 ranging from 0.2 to 2 
ng/ml. TGFβ1 dose-dependently inhibited ATF4’s transcriptional activity (Fig. 12B), and 
these effects were not observed or even reversed at a high dose of TGFβ1 when 
p6xmOSE1-luc (which ATF4 fails to bind due to point mutations  
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Figure 12. TGFβ inhibited ATF4-mediated Osteocalcin expression.  A.  TGFβ 
suppressed Osteocalcin expression in primary calvarial osteoblasts. Northern blot 
analysis on Ocn from total RNA of osteoblasts treated with TGFβ1 (2 ng/ml) or vehicle 
for 10 days upon differentiation. Gapdh, loading control.  B-D. TGFβ dose-dependently 
inhibits ATF4-mediated Ocn transactivation. ROS cells transfected with a construct 
containing 6 copies of ATF4 binding site of the Ocn promoter (p6XOSE1-Luc, B), mutant 
OSE1 that ATF4 fails to bind (p6xmOSE1-Luc, C), or 3 repeats of AP1 binding site 
(negative control, D). 
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(Yang, Matsuda et al. 2004)) or pAP1-luc (an unrelated promoter for another leucine 
zipper transcription factor), were transfected, suggesting that ATF4 is a specific target of 
the TGFβ signaling pathway (Figs. 12 C&D). 
 
ATF4 is required for TGFβ-mediated inhibition on primary calvarial osteoblast 
differentiation and vimentin mediated the effect of TGFβ on ATF4.  
During osteoblast differentiation, osteoblastic genes, such as alkaline 
phosphatase (ALP) and osteocalcin (Ocn), will be turned on, and as a subsequent event, 
bone nodules will be formed. The expression level of ALP and Ocn is thus an indicator of 
the maturation of osteoblasts. Inhibition of osteoblast differentiation by TGFβ is 
accompanied by decrease in ALP activity, suppressed osteocalcin expression, as well 
as a reduced number of bone nodules formed (Centrella, Horowitz et al. 1994) and WT 
in Figs. 13A, B&C). Since TGFβ1 dose-dependently inhibits ATF4’s transactivation 
ability, we next test if this inhibition is crucial in mediating TGFβ’s effect on osteoblast 
differentiation by treating WT and Atf4-/- primary osteoblasts with TGFβ1. In the absence 
of ATF4, TGFβ’s inhibition on ALP activity was totally blocked, the ratio of osteocalcin 
downregulation was partially restored and similar amount of bone nodules were formed  
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Figure 13. TGFβ-mediated inhibition on primary calvarial osteoblast differentiation 
was blocked in ATF4-deficient cells, and vimentin mediated the effect of TGFβ on 
ATF4. A-C. WT and Atf4-/- 
or vehicle for 2 days for ALP activity assay (A); and 10 days for Real-time RT PCR 
analysis on osteocalcin expression (B); and von Kossa assays of mineralized nodules 
(C). D. Western blot analysis on whole cell lysate of WT or Atf4-/-bone marrow stromal 
cells (upper 2 panels) and calvarial osteoblasts (lower 2 panels) upon TGFβ1 (0.5 ng/ml) 
or vehicle treatment for 45 min. Phospho-smad2 was blotted as indicator of intact 
canonical TGFβ signaling. Total smad2, loading control. E. TGFβ1 (0.5 ng/ml) or vehicle 
treated 2T3 cells transfected with p6xOSE1-luc reporter and siRNA-Vim or control. F. 
2T3 osteoblastic cells were treated with TGFβ1 (0.5 ng/ml) or vehicle in the presence 
and absence of siRNA against Vim. Total RNA were collected 2 days following TGFβ1 
treatment.  Northern blot probing Ocn, Vim, and Gapdh RNA. G. 2T3 osteoblastic cells 
were treated with TGFβ1 (0.5 ng/ml) or vehicle in the presence and absence of siRNA 
against Vim. Whole cell lysate were collected 45 min following TGFβ1 treatment. 
Western blot detecting phosphor-smad2 and total smad2 were shown.  
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in the presence of TGFβ1, indicating that TGFβ inhibits osteoblast differentiation in part 
through targeting ATF4 (Figs. 13A, B&C). The abolished effect of TGFβ was not due to 
disrupted TGFβ receptors, as regular TGFβ signaling was intact as shown by normally 
phosphorylated smad2 (Fig. 13D) and smad3 (data not shown) in Atf4-/- osteoblasts 
following TGFβ1 treatment. Taken together, these results suggest that ATF4 serves as a 
crucial target of TGFβ signaling. 
We have previously shown that vimentin inhibits osteocalcin expression through 
suppressing ATF4’s transcriptional activity and thus osteoblast differentiation (Lian, 
Wang et al. 2009). To test directly if TGFβ inhibits ATF4-mediated osteocalcin 
expression via up-regulation of vimentin, we transfected p6xOSE1-luc into 2T3 
osteoblastic cells while silencing vimentin with shRNA against it and then treated the 
cells with TGFβ1 or vehicle. Consistent with Fig. 12B, TGFβ1 inhibits ATF4-mediated 
osteocalcin expression; however this inhibition was abolished when vimentin was 
knocked down (Fig. 13E). As reported, TGFβ1 inhibits endogenous osteocalcin 
expression ((Centrella, Horowitz et al. 1994), Fig.2F compare 1st with 2nd lanes), and the 
endogenous osteocalcin level in 2T3 cells was elevated when vimentin was knocked 
down ((Lian, Wang et al. 2009), Fig.2F compare 1st and 3rd lanes). Similar to the ATF4-
 76 
 
mediated osteocalcin expression as determined by p6xOSE1-luc, TGFβ’s inhibition of 
endogenous osteocalcin transcription was also blocked when vimentin was turned down, 
indicating vimentin is required for mediating this effect (Fig. 13F). To rule out the 
possibility that main players upstream in the TGFβ signaling pathway were defective 
when Vimentin was turned down, we again tested the level of Smad2 phosphorylation 
following TGFβ treatment, and the same extent of phosphorylation was observed in 
control and vimentin-knockdown cells (Fig. 13G), confirming it was the absence of 
vimentin that abolished TGFβ’s effect.  These data collectively imply that ATF4 is 
required for TGFβ-mediated inhibition on primary calvarial osteoblast differentiation, and 
vimentin mediates the effect of TGFβ on ATF4. 
 
TGFβ-neutralizing antibody does not increase bone volume in ATF4-deficient mice 
TGFβ is becoming a therapeutic target in several clinical and preclinical studies 
(Korpal and Kang 2010). Monoclonal TGFβ-neutralizing antibodies, such as 2G7 and 
1D11, have been shown to suppress lung metastases and increase bone mass through 
binding and reducing the biological activity of all three forms of TGFβ (Arteaga, Hurd et 
al. 1993; Pinkas and Teicher 2006; Edwards, Nyman et al. 2010). If ATF4 is an  
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Figure 14. Atf4-/- femur bone mass does not increase upon 2G7 treatment. A & B. 
µCT analysis of trabecular bones from WT and Atf4-/- femurs treated with 2G7 or IgG 
control. N=4 for WT group. N=6 for Atf4-/- group. B. Quantification of Figure A. C. 
Western blot analysis of 3 independent pairs of WT long bones demonstrating an 
inhibited expression of vimentin protein in the presence of 2G7. 
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important target of TGFβ, further inhibiting TGFβ signaling with 2G7 antibody would not 
restore bone mass in the absence of ATF4. This scenario is worth testing not only as  
a proof of concept approach, but also would be practical in the clinic, given the human 
diseases associated with insufficient ATF4 activity (Yang, Matsuda et al. 2004; Dobreva, 
Chahrour et al. 2006). To test this hypothesis, we injected 2G7 intraperitoneally into wild-
type and Atf4-/- mice for 4 weeks. Similar to reports from the 1D11 monoclonal antibody 
study, 2G7 increased bone mass in wild-type mice by more than 30%. However, it fails 
to further increase the bone mass in Atf4-deficient mice (Fig. 14A & B). The resistance to 
2G7 treatment observed in Atf4-deficient bones suggests that ATF4 is an important 
molecule downstream of the TGFβ-mediated bone remodeling event. Since depletion of 
vimentin via RNA silencing abolished the TGFβ-mediated inhibition on ATF4, we next 
investigate if TGFβ exerts its effect through stimulating vimentin expression in vivo by 
comparing WT bones treated with IgG control with those treated with 2G7 TGFβ-
neutralizing antibodies. As shown in Fig. 14C, all three pairs of long bones examined 
displayed a decrease in endogenous level of vimentin when the TGFβ signaling was 
blocked with the 2G7 antibody, indicating that TGFβ induces endogenous vimentin 
expression in bones. 
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Figure 15. TGFβ stimulated Vim expression in osteoblast-related cells. A. Northern 
blot analysis of indicated cells treated with TGFβ1 (0.2 ng/ml) or vehicle for 4 hours. B. 
Whole cell lysate (WCL) from indicated cells administered with TGFβ1 (0.2 ng/ml) or 
vehicle for four hours. C. Effect of protein synthesis inhibitor cycloheximide (CHX) on 
TGFβ-induced upregulation of Vim. D. Western blot analysis of COS1 cells treated with 
MG115 (proteasome inhibitor) or vehicle. Sp1, loading control.  
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TGFβ upregulates vimentin in osteoblasts 
We then investigated whether vimentin is upregulated by TGFβ specifically in 
osteoblasts. It has been reported in C2C12 myogenic cells that TGFβ1 elevated 
Vimentin mRNA levels (Wu, Zhang et al. 2007). However, among all the osteoblatic cell 
lines tested, including bone marrow stromal cells (BMSCs), primary rat calvarial 
osteoblasts, rat osteoblast-like ROS17/2.8 cells, 2T3 cells, and MC3T3-E1 cells, none of 
them displayed increased vimentin RNA levels when treated with TGFβ1 (Fig.15A), 
whereas vimentin protein level was elevated dramatically (Fig.15B).  
The upregulation of a protein can often be achieved through direct accumulation 
of its mRNA, induced protein synthesis, and/or aborted protein degradation. Since the 
level of vimentin mRNA was not changed upon TGFβ treatment, we further investigated, 
at a post-transcriptional level, whether the translation or degradation of vimentin protein 
is affected following TGFβ treatment.  When treated with protein synthesis inhibitor 
cycloheximide, vimentin protein can no longer be elevated by TGFβ, suggesting a 
protein synthesis pathway is involved (Fig. 15C). ATF4 protein is known to accumulate 
when the proteasome degradation machinery is inhibited by MG115 ((Yang and 
Karsenty 2004) and Fig. 15D).  However, this effect was not observed for vimentin 
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protein (Fig.15D). These results collectively imply that the upregulation of vimentin 
induced by TGFβ is mainly mediated by protein synthesis but not through inhibition of its 
protein degradation. 
 
TGFβ induces vimentin translocation in osteoblasts 
As a transcription factor, ATF4 exerts its function through directly interacting with 
its cognate binding site within the nucleus. In a scenario where vimentin suppresses 
ATF4’s transcriptional activity in osteoblasts, one would expect the presence of vimentin 
in the nucleus of osteoblasts. Consistent with our general understanding about vimentin 
as a cytoskeletal protein, under a normal cellular condition, vimentin was largely found 
outside of the nucleus in ROS17/2.8 cells (Fig. 16, control). I then tested whether under 
certain condition, for example, when treated with TGFβ, vimentin would translocate into 
the nucleus of osteoblasts and therefore interact with ATF4 and inhibit its activity.  
Consistent with this hypothesis, when I treated ROS17/2.8 cells with TGFβ, vimentin 
dramatically reorganized and concentrated within the nucleus, further supporting my 
previous observation that vimentin inhibit ATF4’s binding to its cognate binding site, 
OSE1. 
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Figure 16. TGFβ induces vimentin translocation in osteoblasts. Confocal 
immunofluorescent analysis of ROS17/2.8 cells, treated with TGFβ (0.5ug/ml) or vehicle 
for 5 hours, using Vimentin mouse mAb V9 from Santa Cruz (orange color from Cy3-
conjugated secondary antibody). Blue pseudocolor = TO-PRO®-3 (fluorescent DNA dye). 
20x for upper two panels and 63x for lower two panels. Experiments were performed 
with Zeiss LSM 510 inverted confocal microscope from the VUMC Cell Imaging Shared 
Resource. 
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TGFβ-mediated up-regulation of vimentin depends on PI3K-Akt-mTOR pathway 
TGFβ functions through both canonical and non-canonical pathways, and the 
phosphorylation of Smad2/3 is a key signaling event in the canonical pathway 
(Massague 1998). Once phosphorylated, Smad2/3 forms a heterodimeric complex with 
Smad4 (Co-Smad) and associates with additional DNA binding cofactors to turn on 
target genes, and thus modulates downstream events directly at the transcriptional level 
(Massague 1998). On the other hand, in a non-canonical manner, TGFβ induces protein 
synthesis during epithelial to mesenchymal transition (EMT), and this translational 
regulation results from activation by TGFβ of mammalian target of rapamycin (mTOR) 
through phosphatidylinositol 3-kinase (PI3K) and Akt, leading to the phosphorylation of 
S6 kinase 1 (S6K-1) and eukaryotic initiation factor 4E-binding protein 1, which are direct 
regulators of translation initiation (Lamouille and Derynck 2007). This 
PI3K/Akt/mTOR/S6K-1 pathway can be blocked by Wortmannin (a specific inhibitor of 
PI3K), Akt-AA (a dominant negative Akt construct), or Rapamycin (a specific inhibitor of  
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Figure 17. TGFβ induces vimentin via PI3K-Akt-mTOR signaling pathway. A. 
Divergent TGFβ signaling pathways induce translational regulation through smads and 
translational regulation through the PI3K/Akt/mTOR pathway. B. Western blot analysis of 
ROS17/2.8 cells treated with TGFβ1 (0.2 ng/ml) or vehicle and Rapamycin of indicated 
amount (nM) for 1 hr staining for phospho-S6K1 (Thr389)and 4 hrs staining for Vim. C. 
Western blot analysis of ROS17/2.8 cells treated with TGFβ1 (0.2 ng/ml) or vehicle and 
Wortmannin of indicated amount (nM) for 1 hr staining for phospho-Akt (Ser473) and 4 
hrs staining for Vim. D. Western blot analysis of ROS17/2.8 cells transfected with 
dominant negative Akt construct (Akt-AA) blocked the TGFβ-mediated vimentin up-
regulation.  
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mTOR complex 1) (Arcaro and Wymann 1993; Stokoe, Stephens et al. 1997; 
Wullschleger, Loewith et al. 2006; Lamouille and Derynck 2007). Because vimentin 
protein synthesis is stimulated by TGFβ1, we next examined whether this TGFβ-induced 
production of vimentin is blocked when this pathway is suppressed pharmacologically 
with Wortmannin or Rapamycin (Fig. 17A). The phosphorylation of S6K-1 induced by 
TGFβ1 was turned down when treated with 1-5 nM of Rapamycin (Fig. 17B). Similarly, at 
doses as low as 1-5 nM, Wortmannin blocked the phosphorylation of Akt induced by 
TGFβ (Fig. 17C). At both conditions, TGFβ failed to elevate vimentin protein level, 
suggesting a requirement of this pathway in mediating TGFβ’s effect on vimentin (Fig. 
17B & 17C). To rule out the off-target effect of the pharmacological manipulations, we 
then over-express a Akt mutant (Akt-AA) which has previously been shown to prevent 
Akt activation through dominant-negative interference (Stokoe, Stephens et al. 1997). 
Similar to the previous reports, this Akt-AA construct blocked the phosphorylation of 
S6K-1 ((Lamouille and Derynck 2007) and Fig. 17D). The observation that TGFβ failed 
to up-regulate vimentin protein level in the presence of Akt-AA further support the notion 
that the PI3K/Akt/mTOR/S6K-1 pathway is mediating the TGFβ-induced vimentin up-  
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Figure 18. Inhibition of ATF4-mediated Osteocalcin expression by TGFβ was 
abolished when the PI3K-Akt-mTOR pathway was blocked. Luciferase assay of 
ROS17/2.8 cells transfected with p6OSE1-luc followed by 6 hours of the incubation of 
SB505124 (0.4 μM), Rapamycin (5nM), or Wortmannin (5nM), together with TGFβ1 
(1ng/ml) or vehicle. 
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regulation in osteoblasts. Moreover, at the dose of interest, rapamycin abrogated TGFβ-
stimulated vimentin upregulation with the phosphorylation of smad2/3 intact provides 
another piece of evidence that TGFβ1 induces vimentin protein synthesis independent of 
the canonical pathway. 
 
Inhibition on the PI3K-Akt-mTOR pathway prevents the ATF4-mediated 
osteocalcin expression from being inhibited by TGFβ 
We previously established vimentin as an inhibitor against osteoblast 
differentiation (Lian, Wang et al. 2009). Since the inhibition of the PI3K/Akt/mTOR 
pathway blocked the TGFβ-induced vimentin up-regulation, these pharmacological 
treatments may also result in a release of the inhibition on osteoblast differentiation by 
TGFβ. In effect, the treatments of rapamycin and wortmannin have both been 
demonstrated to promote the osteoblastic differentiation (Kratchmarova, Blagoev et al. 
2005; Lee, Yook et al. 2010).  To test if the inhibition on TGFβ-mediated vimentin 
upregulation via targeting the PI3K/Akt/mTOR pathway has a specific effect on the 
ATF4-induced osteocalcin expression, we treated p6OSE1-luc-expressing ROS17/2.8 
cells with rapamycin and wortmannin, with SB505124 as a negative control. In the 
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presence of TGFβ, the ATF4-mediated osteocalcin expression was inhibited, which was 
rescued by rapamycin or wortmannin, but not by SB505124. This is in line with the 
observations that TGFβ failed to upregulate vimentin when rapamycin or wortmannin 
was co-administered (Fig.18). 
 
Decreased bone mass in vimentin-deficient mice 
Based on TGFβ and vimentin’s inhibition on ATF4 and osteoblast differentiation, I 
suspected that vimentin-deficient mice would display high-bone-mass phenotype. I then 
collected and analyzed femur from 3-month-old vimentin-deficient mice. Nevertheless, 
µCT analyses revealed decreased bone volume (BV/TV, Fig.19A), connective density 
(Conn. D, Fig.19B), trabecular numbers (Tb N, Fig.19C) and trabecular thickness (Tb Th, 
Fig.19D), and significantly increased trabecular spacing (Tb Sp, Fig.19E) in these 
vimentin-deficient femur. These observations suggested that absence of vimentin at a 
whole-body level results in abnormalities of bone homeostasis.  
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Figure 19.  µCT analysis showing that adult Vim-/- femur bones display bone 
abnormalities.  Significantly decreased bone volume (BV/TV, A), connective density 
(Conn. D, B), trabecular numbers (Tb N, C) and trabecular thickness (Tb Th, D), and 
significantly increased trabecular spacing (Tb Sp, E) in 3-month old Vim-/- mice 
compared to their WT littermates.  n=7. 
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Discussion 
In this study, we show for the first time that TGFβ up-regulates vimentin in osteoblasts 
through a non-canonical TGFβ pathway resulting in vimentin protein synthesis, which 
mediates the inhibitory effect of TGFβ on osteoblast differentiation. TGFβ inhibits the 
endogenous as well as the ATF4-mediated osteocalcin expression, and these inhibitions 
were abolished when vimentin was targeted by knockdown. ATF4 is an important target 
of TGFβ since osteoblasts lacking ATF4 are less or even not responsive to TGFβ 
signaling as compared to wild-type osteoblasts. In line with this finding, although 
blocking of TGFβ signaling in vivo with 2G7 antibody can elevate bone mass, this effect 
was not observed in ATF4-deficient mice.  Our findings revealed a new mechanism 
whereby TGFβ, through a non-canonical pathway, upregulates vimentin, which in turn 
functionally inhibits ATF4’s transcriptional activity as well as osteoblast differentiation 
and bone formation. 
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ATF4 as a novel transcription factor targeted by the TGFβ signaling during 
osteoblast differentiation 
TGFβ has been well known for inhibiting osteoblast differentiation in vitro. 
However, the mechanism underlying this is not well established. Runx2 has been 
identified as a main transcription factor targeted by TGFβ through Smad3. Since Runx2 
is believed to be the master regulator of osteoblast differentiation, and lies upstream of 
ATF4 with regard to the regulatory pathway, it opens the possibility that the inhibition of 
ATF4-mediated osteocalcin expression by TGFβ is actually relayed by Runx2. However, 
since the inhibitory effect of TGFβ on p6OSE1-luc was observed 4 hours post TGFβ 
treatment, which was much earlier than what was observed on p6OSE2-luc (12 hours); 
this inhibition of ATF4 is likely to be independent of Runx2. Secondly, we were able to 
reverse the inhibition of TGFβ on p6OSE1-luc when rapamycin or wortmannin was 
applied, which does not affect the phosphorylation and activation of Smad2/3. This 
further strengthens the hypothesis that the TGFβ-mediated inhibition on ATF4 is distinct 
from effects on Runx2. 
Although Runx2 is a well-accepted target of TGFβ signaling, since Runx2-/- cells 
can hardly differentiate into osteoblasts or form the bone, it is unlikely to prove that the 
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osteoblast differentiation program is not or less affected by TGFβ in the absence of 
Runx2. However, this becomes possible with the ATF4 model since Atf4-/- osteoblasts, 
although less differentiated, are still functional. The fact that Atf4-/- osteoblasts are 
resistant to or less affected by TGFβ signaling further suggested ATF4 as an important 
target of TGFβ. However, our findings do not lessen the importance of Runx2 as a target 
of the TGFβ signaling. Although Atf4-/- osteoblasts responded much less to TGFβ in 
terms of osteocalcin expression as compared to wildtype cells, they did have less 
transcription of osteocalcin in the presence of TGFβ, suggesting that other targets of 
TGFβ signaling, such as Runx2, are still present in the absence of ATF4. 
 
Vimentin is a molecular relay of the TGFβ signaling in osteoblast 
Vimentin has frequently been reported to be upregulated by TGFβ in non-
osteoblast cells including C2C12 and be associated with several physiological or 
pathological conditions such as EMT and cancer, but the functional relevance of this is 
not fully understood. Here we report that although vimentin mRNA (this makes it 
distinctive to the C2C12 case) is not responsive to TGFβ signaling in osteoblasts, 
vimentin protein is up-regulated by TGFβ in osteoblasts through a non-canonical manner. 
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We previously reported that vimentin directly binds to and inhibits ATF4’s transcriptional 
activity. The fact that TGFβ inhibits ATF4’s transcriptional activity and this inhibition was 
blocked when vimentin was knocked down with siRNA suggested that the up-regulation 
of vimentin by TGFβ is functionally inhibiting the osteoblast differentiation program. Our 
study does not exclude the possibility that vimentin is mediating the effect of other 
signaling events. It has recently been reported that PTH, the intermittent administration 
of which increases bone mass, increases ATF4’s expression and activity in osteoblasts 
(Yu, Franceschi et al. 2008). Interestingly, administration of PTH to human osteoblastic 
cells decreased the de novo biosynthesis of vimentin (Lomri and Marie 1990), giving the 
possibility that vimentin serves as a molecular switch transmitting extracellular clues to 
osteoblasts.  
We previously reported that both vimentin mRNA and protein level were 
gradually turned down during osteoblast differentiation. However, TGFβ was only able to 
control the vimentin protein levels. This indicates that other signaling pathways are 
involved in regulating its transcription and/or RNA stability. 
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Clinical implications of the TGFβ-mediated inhibition of ATF4 
TGFβ is becoming a therapeutic target in several clinical and preclinical studies 
(Korpal and Kang 2010). Monoclonal TGFβ-neutralising antibodies, such as 1D11, have 
been shown to increase bone mass through binding and reducing the biological activity 
of all three forms of TGFβ (Edwards, Nyman et al. 2010). With the knowledge that ATF4 
lies downstream of signaling and the observation that Atf4-/- mice do not respond to 
TGFβ neutralizing antibody 2G7, we may provide a molecular basis for clinical cases 
involving a small population of patients who do not respond to bone restoring therapies 
that involve inhibiting TGFβ signaling events. For example, ATF4 has been suggested 
as a critical substrate of RSK2, the mutation of which leads to Coffin-lowry syndrome, a 
mental retardation condition associated with skeletal abnormalities. As a result, Coffin-
lowry patients may not respond to the TGFβ based treatment due to the low activity of 
ATF4, a scenario comparable to the Atf4-/- model. 
 
Phenotypes of vimentin-deficient mice 
Given the inhibitory effect of vimentin observed in this study on ATF4 and 
osteoblast differentiation and the expression pattern of vimentin at both RNA and protein 
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level, the low-bone-mass phenotype of vimentin-null mice is unexpected, since all else 
being equal, knocking out of vimentin in osteoblast should result in a better osteoblast 
differentiation and subsequent high bone mass. Several factors may contribute to our 
observations: 1) the mouse model I relied on is a whole-body knockout, in which 
vimentin is mutated in both osteoblasts and osteoclasts. Osteoclasts may be hyper-
activated in the absence of vimentin in a direct and/or indirect manner. Vimentin may 
serve as a direct inhibitor within osteoclasts to suppress their differentiation or activity, 
but this is not very likely due to a low expression level of vimentin in osteoclasts; 
alternatively, given that osteoblasts facilitate osteoclast differentiation though secreting 
factors such as RANKL, the inactivation of vimentin in osteoblasts may indirectly activate 
osteoclasts in vivo. 2) Vimentin may be required for inhibition of osteoblast differentiation 
in osteoprogenitor cells that give rise to a sufficient pool of preosteoblasts.  Inactivation 
of vimentin may release this inhibition leading to a premature osteoblast differentiation.  
The net result in adult mice may be a decreased number of active bone matrix-secreting 
osteoblasts and less bone. 3) Inactivation of vimentin may systematically lead to 
unfavorable changes in circulating factors such as estrogen and vitamin D, which may 
negatively affect bone homeostasis.    
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CHAPTER IV 
 
CONCLUSIONS, DISCUSSION AND FUTURE DIRECTIONS 
 
ATF4 is an important transcription factor required for timely osteogenesis, 
accrual bone mass maintenance during adulthood, as well as proper and adequate 
osteoblastogenesis. As a result, it is of no surprise that ATF4 serves as a critical 
regulatory point tightly monitored under the osteoblast differentiation program. In 
particular, this molecule is highly regulated at a post-transcriptional level, where 
proteasome-mediated degradation, phosphorylation-based activation, and protein-
protein interaction all affect the ultimate function of ATF4 in the context of osteoblast 
differentiation and tissue-specific gene expression. As a transcription factor, ATF4 is 
directly involved in the process of osteoblast differentiation in part by directly turning on 
the transcription of osteoblast-related genes. In physiological context, most of the tissue-
specific differentiation is triggered initially by extracellular clues, such as Parathyroid 
Hormone (PTH) and Transforming Growth Factor beta (TGFβ). It has recently been 
reported that PTH, the intermittent administration of which increases bone mass, 
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increases ATF4’s expression and activity in osteoblast, and the anabolic actions of PTH 
in bone are severely impaired in mice lacking ATF4  (Yu, Franceschi et al. 2008). Our 
work provides the first piece of evidence that ATF4 is also the target of the TGFβ 
signaling pathway. During osteoblast differentiation, the osteocalcin gene is gradually 
turned on, a hallmark of osteoblast maturation. TGFβ inhibits the terminal differentiation 
of osteoblasts, accompanied by decreased bone nodule formation and suppressed 
elevation of osteocalcin expression. Since osteocalcin is identified as a target of ATF4 in 
osteoblasts by direct promoter binding assay (chromatin immunoprecipitation and gel 
shift assay) and reporter assay in vitro and a genetic model in vivo, we tested whether 
ATF4 is functionally regulated by TGFβ by using reporter assay with a luciferase reporter 
under the control of 6 copies of Osteoblast Specific Element 1 (OSE1), named p6OSE1-
luc, which was documented as the ATF4’s binding site in the osteocalcin promoter. The 
activity of p6OSE1-luc, but not that of p6mOSE1-luc which ATF4 fails to activate, 
gradually decreased when increasing amount of TGFβ1 was given, with the protein level 
of ATF4 unchanged, suggesting that TGFβ1 dose-dependently inhibits ATF4’s 
transcriptional activity.  
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Deficiency in ATF4 or inhibition of ATF4’s transactivation ability, for example, by 
FIAT, a leucine zipper nuclear molecule lacking a basic domain for DNA binding that 
interacts with ATF4 to repress its transcriptional activity, has been shown to result in low 
osteocalcin expression and osteopenia. We reason TGFβ may exert its inhibitory effect 
on osteoblast differentiation and bone mass partially through repressing ATF4, and if this 
hypothesis holds true, treatment of TGFβ on Atf4-deficient osteoblasts should result in 
less inhibitory effect. To monitor the level of osteoblast differentiation, we measured ALP 
activity, the number of bone nodule formed, and the expression of osteocalcin, all of 
which have been shown to be inhibited by TGFβ. Interestingly, although a comparatively 
low dose of TGFβ1 ranging from 0.1-0.2 ng/ml significantly down-regulated ALP activity, 
bone nodule formation, and expression of osteocalcin in wild-type calvarial osteoblasts 
as previously reported, these inhibitions were much more mild in the absence of ATF4. 
These in vitro experimental results established ATF4 as a functional target of TGFβ 
signaling in these bone-forming cells. In vivo, several strategies for disrupting TGFβ 
signaling have been developed, such as 1D11 and 2G7, the TGFβ-neutralizing 
antibodies blocking all three forms of TGFβ. Suppression of the TGFβ signaling post-
natally has been known to result in anabolic effects. For example, a 4-week treatment of 
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1D11 increased BMD, trabecular thickness and BV/TV, accompanied by elevated 
osteoblast numbers (Edwards, Nyman et al. 2010). Similarly, comparing the effect of 
2G7 treatment on wild-type and Atf4-null mice will give insights to the role of ATF4 as an 
in vivo target of TGFβ.  While administration of 2G7 on wild-type mice results in similar 
phenotypes as 1D11 such as increased bone mass, this effect was impaired when ATF4 
is mutated, confirming in vivo that ATF4 is involved in transmitting the effect of TGFβ in 
the maintenance of bone mass.  
Mutations of ATF4 have not yet been reported in any known human disease so 
far, and this may suggest how vital ATF4 can be as a multifunctional transcription factor 
functioning in many aspects of developmental biology. However, in the clinic, several 
pathological conditions associated with skeletal defects have been linked to the 
inadequate activity of ATF4, including Coffin-Lowry syndrome (caused by inactivating 
mutation of Rsk2 gene) and a genetic disease resulting in cleft palate and low bone 
mass (caused by inactivating mutation of Satb2 gene) (Yang, Matsuda et al. 2004; 
Dobreva, Chahrour et al. 2006). Although not directly tested, our finding of the resistance 
to TGFβ-neutralizing antibody treatment observed in Atf4-deficient mice suggests a 
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potential limitation in the application of anti-TGFβ therapy in these patients who may 
resemble an ATF4-null condition to some certain extent.  
TGFβ is known to exert its function through both canonical and non-canonical 
pathways, depending on whether the phosphorylation of Smad2/3 is required. A classic 
view of the TGFβ-mediated inhibition of osteoblast differentiation mainly involves Runx2, 
the master regulator of osteoblast differentiation. TGFβ represses Runx2’s 
transactivation ability in a canonical manner, through the phosphorylation of Smad3, 
which in turn physically interacts with Runx2 at Runx2-responsive elements, resulting in 
repression of Runx2 and other osteogenic genes’ expression (Alliston, Choy et al. 2001). 
This smad-mediated inhibition of Runx2 illustrates how the TGFβ signaling directly 
targets the transcriptional machinery. However, other mechanisms beyond the canonical 
pathway also exist. The fact that SB505124, a small molecule inhibiting TGFβ-induced 
Smad2/3 phosphorylation, is unable to rescue TGFβ’s suppression on ATF4 suggests 
other pathways may also play a role. We therefore tested the effect of Rapamycin and 
Wortmannin, inhibitors specifically targeting a branch of the non-canonical TGFβ 
signaling pathway, where TGFβ induces the phosphorylation of PI3K, which in turn 
activates Akt, and subsequently mTOR (Lamouille and Derynck 2007; Zhang 2009). 
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Indeed, Rapamycin and Wortmannin, but not SB505124, reverse the inhibitory effect of 
TGFβ on ATF4’s transcriptional activity, implying that TGFβ also employs the non-
cannonical pathway and targets gene expression indirectly in a more sophisticated way.  
Both Runx2 and ATF4 are expressed in an osteoblast-predominant manner. 
Although the mechanism is not totally unveiled, these two proteins have been found to 
activate the promoter of several identical genes, including osteocalcin, Indian hedgehog, 
and RANKL. Our observation that, in addition to Runx2, ATF4 is another transcription 
factor regulated by the TGFβ signaling pathway provides one more piece of evidence of 
how these two molecules are functionally related. Yet, three levels of differences 
distinguish ATF4 and Runx2 in the context of the TGFβ modulation. First, the effect of 
TGFβ1 on Runx2 was not observed until 10 hours post treatment, while the ATF4-
mediated transcription was inhibited by TGFβ as early as 6 hours following treatment, 
suggesting that the machinery corresponding for the effect on ATF4 is comparatively 
early-responsive and independent of the suppression of Runx2. Second, although not 
directly tested, since TGFβ1 has been shown to inhibit Runx2’s transactivation ability 
through phosphorylated Smad3, which can be blocked pharmacologically by SB505124. 
The application of SB505124 should prevent the suppression on Runx2. However, ATF4 
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is inhibited to the same extent by TGFβ1 in the presence or absence of SB505124. This 
discrepancy again suggests that distinctive mechanisms are involved in targeting ATF4 
and Runx2. Thirdly, at a comparatively low dose (ranging from 0.1 to 0.2 ng/ml), TGFβ1 
was not able to block several aspects of calvarial osteoblast differentiation in the 
absence of ATF4, as demonstrated by unchanged ALP activity and similar number of 
bone nodules formed when challenged by TGFβ1. This indicates that, under certain 
conditions, ATF4 can be the main target of the TGFβ signaling event, independent of 
Runx2. However, I suspect that a high dose of TGFβ1 would also involve Runx2 as an 
important regulatory target and in that scenario, Atf4-deficient osteoblasts will also 
respond, perhaps less severely, to TGFβ1. Indeed, the observation that, although much 
less effective, osteocalcin gene expression is still subject to TGFβ1’s regulation in Atf4-
deficient cells suggests that Runx2 may be affected by TGFβ1 mildly in these cells.  
Through a pull-down assay with ATF4 as the bait and nuclear extract from 
osteoblast-related ROS17/2.8 cells as the pool of prey, we discovered the novel 
interaction between the intermediate filament vimentin and our transcription factor of 
interest, ATF4. This finding was supported by co-immunoprecipitation assay in 
mammalian cells and further by pull-down assay with purified recombinant GST-tagged 
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vimentin and Histidine-tagged ATF4, and various truncated forms of each. These 
experimental observations for the first time provide direct evidence for the hypothesis 
proposed by Capetanaki et al., who, upon computational analysis,  predicted molecular 
interactions between vimentin and several CREB transcription factor family members 
based on their structural similarities localized to the important leucine zipper domains 
capable of coiled-coil interactions (Capetanaki, Kuisk et al. 1990). In addition, in vitro 
studies have suggested high binding affinity of vimentin to a variety of synthetic and 
natural nucleic acids (Hartig, Huang et al. 1997), and this DNA-binding mediates 
transport of vimentin into the nucleus of cultured cells (Hartig, Shoeman et al. 1998). 
These experimental clues converge at the hypothesis that vimentin not only fulfills 
general cytoskeletal functions in the cytoplasm but also participates in DNA-based 
events taking place in the nuclear interior. We then tested the functional relevance of the 
ATF4-vimentin interaction. Ectopic expression of vimentin in COS1 cells suppressed the 
ATF4-mediated transcription of osteocalcin gene, and vice versa, depletion of vimentin 
through RNA interference elevated osteocalcin expression significantly. Furthermore, 
GST-tagged vimentin dose-dependently inhibit ATF4’s DNA binding ability in a gel-shift 
assay. Further on a cellular level, we found that overexpression of vimentin in MC3T3-
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E1 osteoblasts led to a delay in osteoblastogenesis. Consistent with the inhibitory effect 
of vimentin, both vimentin mRNA and protein are down-regulated during osteoblast 
differentiation. This makes biological sense in terms of paving the way for further 
differentiation and maturation. These data, from a functional point of view, suggest that 
vimentin does not simply provide structural support to cells, but also actively participates 
in transcriptional control in the progression of osteoblast differentiation. Further 
experiments could be done to confirm or test mechanistically the vimentin-mediated 
regulation of ATF4. For example, in addition to the gel-shift assay, we can use the 
Chromatin-Immunoprecipitation (CHIP) assay to directly test whether the overexpression 
of vimentin can actually inhibit the ATF4-DNA interaction in mammalian cells, and if so, 
whether this is due to the reduced amount of ATF4 reaching the nuclei or a less efficient 
binding ability of ATF4 due to interaction with vimentin. In the former scenario, I would 
expect to detect less ATF4 from the nuclear extracts when vimentin is over-expressed.  
Several pieces of information led us to hypothesize that TGFβ regulates the 
expression of vimentin in osteoblasts. Firstly, the presence of TGFβ-neutralizing 
antibody, 2G7, blocked the expression of vimentin in vivo. Secondly, consistent with the 
observation that vimentin level is gradually turned down during osteoblast differentiation, 
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in a natural setting, a spontaneous decrease in TβRI and TβRII was observed as human 
bone marrow stromal cells (BMSCs) progress from osteoprogenitor cells to maturing 
osteoblasts and a decrease of TGFβ/receptor interactions was reported during 
osteoblast differentiation (Centrella, Casinghino et al. 1995; Takeuchi, Nakayama et al. 
1996; Walsh, Jefferiss et al. 2003). Thirdly, in C2C12 cells and during EMT transition, 
TGFβ have been documented to up-regulate vimentin levels (Margetts, Bonniaud et al. 
2005; Wu, Zhang et al. 2007). We therefore investigated specifically if TGFβ up-
regulates vimentin in osteoblasts. For all the osteoblast-related cells we have tested, 
including BMSCs, calvarial osteoblasts, 2T3 cells, MC3T3-E1 cells, and ROS17/2.8 cells, 
TGFβ1 induces vimentin protein expression, while leaving its mRNA level unchanged. In 
a canonical TGFβ signaling event, the activation of TβRI leads to Smad2/3 mediated 
transcriptional regulation. The unaffected level of vimentin mRNA implies that TGFβ 
elevates vimentin through a non-canonical pathway. Supporting this notion, the increase 
in vimentin protein level was abrogated by rapamycin and wortmannin, both of which 
hinder a branch of non-canonical pathways (mediated by PI3K-Akt-mTOR) which is 
implicated in the enhancement of the cap-dependent translation. Moreover, at the 
effective dose, neither rapamycin nor wortmannin affected the phosphorylation of 
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Smad2/3 induced by TGFβ1, further confirming that TGFβ1 upregulates vimentin in a 
smad-independent manner.  
Suppression of PI3K and mTOR signaling using inhibitors such as wortmannin, 
rapamycin, and NVP-BEZ235 has been shown to promote osteogenesis in vitro, as 
measured by an increase in mineral formation or bone nodule formation and an 
upregulation of genes involved in osteogenesis including osteocalcin (Ogawa, Tokuda et 
al. 1998; Kratchmarova, Blagoev et al. 2005; Fitter, Dewar et al. 2008; Lee, Yook et al. 
2010; Martin, Fitter et al. 2010). These findings have been explained by an increase in 
Runx2 levels following the pharmacological treatments. However, since the 
overexpression of Runx2 under the control of a 2.3-kb mouse Col1a1 promoter inhibits 
mature osteoblast formation, as demonstrated by the severe reduction of osteocalcin 
expression from both the bones and calvarial osteoblasts of the Runx2-overexpressing 
mice, and diminished number of terminally differentiated osteoblasts (Liu, Toyosawa et 
al. 2001; Geoffroy, Kneissel et al. 2002; Kanatani, Fujita et al. 2006), other mechanisms 
may be considered. In effect, vimentin may be the candidate molecule, as suppression 
of the PI3K/Akt/mTOR pathway blunts the increase in vimentin level, and a decrease of 
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vimentin level has been associated with upregulation of osteocalcin expression or even 
maintainance of the level of osteocalcin in the presence of TGFβ. 
We also examined if there is a causal relationship between the up-regulation of 
vimentin and inhibition on ATF4’s transactivation activity by TGFβ. This is made possible 
by the availability of a luciferase reporter, p6OSE1-luc, which is specifically activated by 
ATF4. The level of ATF4-activated p6OSE1-luc is turned down upon TGFβ treatment, 
whereas down-regulation of vimentin through RNA interference hinder this effect, 
suggesting a novel axis composed of TGFβ-vimentin-ATF4 which serves as a brake 
against osteoblast terminal differentiation. Upon binding to its receptor, TGFβ first 
induces the expression of vimentin through the PI3K-Akt-mTOR non-canonical pathway, 
and vimentin, through binding to ATF4, inhibits its transcriptional activity, resulting in 
repression of osteoblast terminal differentiation. Consistently, depletion of vimentin 
prevents ATF4 from being inhibited by TGFβ, and the absence of ATF4 further abolishes 
the inhibition of TGFβ on osteoblast differentiation.  
To test the existence of the TGFβ-vimentin-ATF4 axis in vivo, in addition to 
treating wild-type and Atf4-deficient mice with the TGFβ neutralizing antibody, it will also 
be necessary to compare the effect of 2G7 on wild-type with that of vimentin-deficient 
 111 
 
mice. A straightforward outcome would be an increase in BV/TV in wild-type mice, but a 
smaller or even no increase in vimentin-deficient mice, given that vimentin may be 
required to mediate TGFβ’s inhibitory effect in osteoblasts. Although not likely, the bone 
mass may still be increased to a similar extent in vimentin knockout mice. This is a 
possibility because, first of all, although the TGFβ-vimentin-ATF4 axis exists 
independently from the canonical signaling, impairment of Smad2/3 phosphorylation 
leads to a dramatic increase in the osteoblast differentiation. Although treatment of 
SB505124 does not increase ATF4-mediated p6OSE1 controlled luciferase expression, 
this does not exclude that in a physiological context, expression of other endogenous 
target of ATF4 may still be elevated by SB505124. Second of all, within non-canonical 
TGFβ signaling, vimentin may not be the exclusive factor withholding ATF4’s activity in 
vivo. In order to elucidate the relevance of vimentin in mediating TGFβ’s impact on ATF4, 
we need to thoroughly examine all the known ATF4-targeted genes’ expression in 
osteoblasts from vimentin-null mice after 2G7 administration.  
We have shown in vitro that overexpression of vimentin in MC3T3-E1 osteoblasts 
has a strong effect in delaying osteoblast differentiation. Yet, this phenomenon has not 
been examined in vivo. Two genetic strategies can be used to illustrate the physiological 
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role of vimentin – to either over-express vimentin or knockout vimentin from the genome. 
In order to test the role of vimentin in a spatial- and temporal-specific manner within 
osteoblasts, we can generate transgenic constructs of vimentin driven by either a 2.3kb 
Col1A1 promoter, which over-expresses vimentin in both immature and mature 
osteoblasts, or an OCN promoter, which specifically over-expresses vimentin only in 
mature osteoblasts. Because vimentin is progressively down-regulated during osteoblast 
differentiation, I would expect that over-expressing vimentin in late osteoblasts will cause 
a more dramatic effect than in early osteoblasts, in which a high level of vimentin is 
maintained and perhaps a plateau has already been reached. If this holds true, a similar, 
if not identical, low-bone-mass phenotype will likely be observed in Col1A1-vim and 
OCN-vim mice. Conversely, knocking out vimentin from the genome will allow us to 
eliminate its inhibitory action and result in a high-bone-mass phenotype under a 
simplified scenario. However, since bone mass is a net result of both bone formation by 
osteoblasts and bone resorption by osteoclasts, knocking out vimentin as a whole may 
lead to complicated consequences, especially if vimentin is also involved in 
osteoclastogenesis and subsequent function. Furthermore, because vimentin is required 
by several cell types during migration, disruption of vimentin in osteoprogenitors, which 
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need to migrate to relevant sites in a timely manner, will result in an accelerated 
osteoblastogenesis, but not necessarily better bone formation, due to uncoupled bone 
formation resulting from impaired migration of osteoprogenitors. Counting the number of 
osteoblasts successfully reaching bone surface in vimentin-deficient mice will provide 
clues of whether this is happening physiologically. Alternatively, we can avoid a 
complicated interpretation by utilizing the conditional knockout technology, with which 
vimentin is knocked out only in a later stage during osteoblast differentiation, after the 
arrival of osteoprogenitors on to the bone surface. This is technologically possible in the 
near future since the EUCOMM production center has generated a conditional-ready 
targeting vector of vimentin, where its critical exon is surrounded by loxP sites, and ES 
cells carrying this construct are planned to be made in this year. We could then 
specifically knock out vimentin during the later differentiation state by Cre recombinase 
under the control of osteocalcin promoter.  
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